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1. Summary and Aims of the thesis 
 
A lively interest in the cannabis plant can be verified for a long time. As a drug in the 
traditional medicine, different pieces of the cannabis plant were used against a 
palette of diseases such as pain (head- and stomach-ache), menstrual problems and 
diarrhoea. Further, it was used as a sedative and to induce sleep [1].  
 
At the beginning of the 20th century, a scientific interest for cannabis has emerged. 
Research was done to detect the pharmacokinetic and pharmacodynamic effects of 
cannabis. The discovery of the endogenous cannabinoid system opened a broad 
field for research. This system gradually helped to better understand the molecular 
mechanisms of the cannabis effects. Links to other modulating or regulatory systems 
in our body are now possible [2].  
 
The special applications of cannabis in traditional medicine, have to be clinically 
investigated with the scientific knowledge of today. Some applications are already 
established. The United States Food and Drug Administration (FDA) approved 
MarinolTM (a soft gelatine capsule containing THC dissolved in sesame oil) to treat 
nausea and vomiting associated with cancer chemotherapy in patients who have 
failed to respond adequately to conventional therapies. The antiemetic effects are 
comparable to conventional therapy such as domperidone [3]. Furthermore, the FDA 
approved MarinolTM to treat appetite loss associated with weight reduction in people 
with acquired immunodeficiency syndrome (AIDS). It was shown in recent studies 
that THC or cannabis preparations have a promising potential as a releasing factor, 
in moving disorders and as a pain reducer in patients suffering from multiple 
sclerosis. Therefore further research is required. 
 
Worldwide, the use of natural cannabis products for medical purposes is practically 
not allowed. In contrast, drugs containing synthetic cannabinoids like dronabinol, a 
synthetic THC are often exempt from these restrictions. Synthetic products, however, 
have a disadvantage: they do not contain a well-balanced combination of active 
substances which can be found in the natural cannabis plant. Patients having 
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consumed natural cannabinoids for their medical therapy report more adverse effects 
after the administration of synthetic cannabis preparations [4, 5]. The principle of 
phytotherapy is the treatment with a mixture of bioactive compounds. The idea is that 
a complex pathophysiological process can be influenced more effectively and with 
fewer adverse effects by a combination of several low-dosage extract compounds 
than by a single isolated compound [6]. Therefore, it is important to develop and 
clinically investigate oral cannabis extract formulations to prove pharmacodynamic 
and pharmacokinetic properties and to compare them with the existing synthetic THC 
products and against placebo is important.  
 
The aim in project one of the present work (publication 3, chapter 3.3) was to 
approve the performance of an open, randomised, single-center, three-periods cross-
over study with different, standardised Cannabis sativa L. extract capsule 
formulations and MarinolTM, to analyse the pharmacokinetics and pharmacodynamics 
of the cannabinoids and to evaluate the best Cannabis sativa L. extract capsule 
formulation in this clinical phase I study for a possible future implementation as a 
new, concomitant medication in cancer, HIV and AIDS therapies. 
 
In the first study part, the heating-effect on the relative content of cannabinoids in the 
Cannabis sativa L. extract capsule formulation was assessed. Data were compared 
to the commercial formulation MarinolTM. The reason for this is that in naturally grown 
Cannabis sativa L., up to 95% of the occurring total cannabinoids (THCtot) are in the 
form of ∆9-tetrahydrocannabinolic acid A (THCA-A)
. 
By heating, THCA-A is 
quantitatively decarboxylised to phenolic THC [7]. Although THCA-A is described as 
pharmacologically inactive and devoid of psychotropic effects [7], reports of popular 
medicinal use of unheated cannabis or cannabis preparations show pharmacological 
effects often accompanied with a lower rate of adverse effects (anecdotal reports). It 
also possesses some anti-inflammatory and analgesic effects [8]. Recently, it was 
shown that unheated cannabis extracts were able to inhibit tumor necrosis factor 
alpha in macrophage culture and peripheral marcrophages after LPS stimulation [9]. 
In the second study part, the effect of different Cannabis sativa L. extract capsule 
formulations, containing different concentrations of TPGS, on the bioavailabilities of 
different active cannabinoids was assessed. The reason for this is that the enteral 
 Summary and Aims of the thesis   
 13 
absorption of cannabinoids under optimal conditions would be up to 95%, but due to 
the extensive liver first-pass metabolism and the poor solubility the effective, 
measured bioavailability is very low (10-20%) [10]. Further the activity of P-
glycoprotein (P-gp), a membrane efflux transporter also expressed in the intestine, 
may reduce the oral bioavailability of cannabinoids. Therefore, it is important to 
increase the bioavailabilities of oral drugs with substances possessing absorption 
enhancement, drug solubilising and inhibiting effects on P-gp. Previous work has 
shown that D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) has an 
accelerating effect on gastrointestinal transit and a modulating influence on drug 
absorption in humans [11]. A P-gp inhibition could be demonstrated [12-14].  
 
Further study endpoints were a) to assess the relative bioavailabilities of THC and its 
metabolites assessed as area under the plasma concentration/time curve from time T 
= 0 h extrapolated to infinity (AUC(0-∞)), b) to assess the relative tolerability and 
safety of six different oral formulations of 20 mg THCtot (THC and THCA-A), c) to 
assess the effect of six different oral formulations of 20 mg THCtot on psychomotor 
function assessed as simulator assisted evaluation of driving ability, d) to assess 
repetitive heart rate, blood pressure and a visual analogue scale (VAS) for 
psychotropic effects. 
 
The pharmacokinetics of the cannabinoids was highly variable between the subjects. 
Due to this variability, no statistically significant differences between the AUC of the 
different forms could be detected, neither in part I nor in part II of the study. Addition 
of different amounts of TPGS resulted in an increase in relative bioavailability of the 
sum of cannabinoid metabolites (THC + 11-OH-THC + THC-COOH + CBN) to 
122.5% (7.5% TPGS), 134.9% (0.5% TPGS) and 135.9% (5% TPGS) compared with 
the AUC of the unheated extract (=100%) in study part I. The administration of 
cannabis extracts as well as the addition of TPGS leads to a qualitatively different 
pattern of cannabinoid metabolites. After administration of the unheated extract, a 
significantly higher proportion of THC AUC and a significantly lower THC-COOH AUC 
of all cannabinoids were observed compared to the heated extract or MarinolTM. After 
administration of the synthetic MarinolTM, no plasma concentrations of CBD could be 
detected. This was expected, since THC is not converted to CBD in vivo and is found 
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only in cannabis plants. Heating of extracts decreased the proportion of CBD 
significantly. The future approach will address further research. Further, clinical 
studies with the 0.5% or 5% TPGS Cannabis sativa L. extract capsule formulations 
may be helpful. The study should be placebo controlled and later tested in the future 
patient group. 
 
In the present work, only the pharmacokinetics of the study are described, evaluated 
and discussed. The pharmacodynamic results are reported in two separate 
publications. 
 
The aim in project two (publication 1, chapter 3.1) was the development of a sensitive 
high-performance liquid chromatographic separation method with tandem-mass 
spectrometry detection for the simultaneous detection of THC and its major 
metabolites 11-OH-THC and THC-COOH as well as the components CBD and CBN 
in human EDTA-plasma and urine. Optimal conditions for the analysis method, such 
as extraction procedure, matrices, column, quality controls, wavelength, mobile 
phases, run time, optimal separation (gradient, retention times), temperature, 
voltages, vacuum and internal standards, resulting in the best sensitivity and 
selectivity, were developed in preliminary experiments. The validation of the method 
was performed according to the FDA Good Laboratory Practice guidelines, 
containing linear measuring range, quantification, lower limit of quantification (LLOQ), 
lower limit of detection (LLOD), quality controls, precision, accuracy, recovery, 
stability and matrix effects. In conclusion, the described high-performance liquid 
chromatographic separation method with tandem-mass spectrometry detection 
showed a satisfactory overall analytical performance well suited for applications in 
medical science. The combination of SPE/LLE, LC and APCI-MS/MS represents an 
attractive alternative to the well-established technique of GC-MS. 
 
In project three (publication 2, chapter 3.2), the sensitivity and specificity of two 
immunoassays (CEDIA, FPIA) were established in urinary samples from volunteers 
receiving oral synthetic THC or Cannabis sativa L. extracts. Urinary THC-COOH 
excretion was evaluated by the immunoassays with a cut-off value of 50 ng/ml as 
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well as the described LC-MS/MS method (gold standard) with a cut-off value of 15 
ng/ml. It was demonstrated that LC-MS/MS is an excellent confirmation method for 
immunoassays allowing the qualitative and quantitative detection of many 
cannabinoids. The ROC analysis indicated that the FPIA test discriminates better 
between users and non-users than the CEDIA test. The results of both 
immunoassays show that the National Institute on Drug Abuse (NIDA) set general 
immunoassay cut-off of 50 ng/ml is possibly not applicable for analysis of samples 
from persons consuming the Cannabis sativa L. extracts orally instead of smoking. It 
has to be discussed, whether a lower cut-off value would be advantageous. It is 
supposed that metabolite concentrations differ strongly depending on the route of 
application. The amount and appearance of different metabolites may disturb the 
immunoassay methods. The hydrolysation procedure showed a total transformation 
of the THC-COOH-glucuronides to THC-COOH confirmed by the nearly 100% 
agreement of the concentrations in the different samples analysed with the two 
immunoassays and the LC-MS/MS comparisons. The glucuronide is automatically 
detected together with THC-COOH and it is direct de-glucuronated in the APCI unit 
of the detector. 
 
The present work is structured into a theoretical and a publication section. The 
theoretical section gives an overview about cannabis, mass spectrometry, assay 
validation and GLP-guidelines related to the aspects used in the work of this thesis. 
The publication section describes the results of the investigations, submitted for 
publication to different scientific journals. 
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2. Introduction 
 
2.1. Biological Part 
 
2.1.1. Cannabis sativa L. 
 
2.1.1.1. Botanical characteristics [15-17] 
 
Cannabis sativa L. belongs to the family of cannabaceae and grows in all warm and 
temperate zones, except in the tropical rain forest. It is an annual plant, which can 
grow up to 5m. When planted closely together, the plants are variously branched or 
even unbranched. The cannabis plant is covered with tiny hairs. The leaves and 
branches are paired at the bottom and arranged alternating higher on the stem. The 
leaves have a delicate stem which is about 6 cm long. They are pinnate in a dactyloid 
form. The 5 to 9 leaflets are mostly narrowly lanceolate. They are coarsely sawed 
and toothed and have a long protracted pointed tip. Cannabis is a dioecious plant 
which means that the flowers are either female or male. Female plants are very leafy 
up to the top while male plants have fewer leaves on the inflorescence which are 
much further apart. The glands of the female flowers, secret drops of resin, which are 
produced under hot conditions. Male plants die after the pollination. In the absence of 
male plants, female ones produce more flowers covered with THC producing glands. 
A function of the resin glands is the protection of the plant from animals. The greyish 
or brownish fruit is physically an achene. It is ellipsoid, smooth, slightly compressed, 
about 2.5 - 5 cm long and the diameter is 2 - 3.5 cm. 
 
2.1.1.2. Chemical constituents of Cannabis [15, 18] 
 
More than 480 compounds were detected in Cannabis sativa L. of which more than 
65 are cannabinoids (“phytocannabinoids”). Cannabinoids are specific and 
characteristic components of the Cannabis plant. They are nitrogen free, quite 
lipophilic, phenolic and have a C21-skeleton. Cannabinoids are derived from a 
monoterpene and a phenol or a phenolic acid. According to the difference in the 
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terpene part of the molecule, cannabinoids can be classified in five types as well as 
some minor cannabinoid classes: the cannabigerol, the cannabichromene, the 
cannabidiol, the tetrahydrocannabinol and the cannabinol type. The cannabinol type 
is an artefact formed by oxidation of biogenic cannabinoids. This type is produced 
during storage or extraction. Structures of the cannabinoid types are presented in 
Figure 1. 
 
Cannabigerol type Cannabichromene type Cannabidiol type 
O
R2
R3O
R1
 
OH
R1
R2O
 
OH
R1
R2O
R3
 
R1 = H or COOH 
R2 = C3- or C5-sidechain 
R3 = H or CH3 
R1 = H or COOH 
R2 = C3- or C5-sidechain 
 
R1 = H or COOH 
R2 = C1-, C3-, C4- or C5-sidechain 
R3 = H or CH3 
 
Tetrahydrocannabinol type Cannabinol type 
OH
R1
R2O
R3
 
O
R2
R3O
R1
 
R1, R3= H or COOH 
R2 = C1-, C3-, C4- or C5-sidechain 
 
R1 = H or CH3 
R2 = H or COOH 
R3 = C1-, C3-, C4- or C5-sidechain 
Figure 1: Structures of the different cannabinoid types 
 
The characteristic smell of the hemp plant is caused by an essential oil produced by 
the circular glands. This oil contains phenylpropane derivatives (e.g. eugenol, cis- 
and trans-anethol) and mono- and sesquiterpenes (e.g. humulene, α- and β-pinene, 
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limonene, β-caryophyllene, caryophyllene oxide). Furthermore, it contains small 
amounts of other phenolic compounds (e.g. dihydrophenanthrene derivatives, 
spiroindane, dihydrostilbene), flavonoids, amino acids, sugars and nitrogen-
containing compounds (amines, amides). 
 
2.1.1.3. Cannabis products [15, 16, 19, 20] 
 
a. Cannabis herb 
 
The herb (“Marihuana”, “Marijuana”) consists of the dried leaves and blooms of the 
cannabis plant. The THC content is 1 - 25 %. 
 
b. Cannabis resin 
 
The brownish resin (“Hashish”) is produced by the circular glands of the female 
inflorescence. For recreational use, Hashish is often pressed into bars or cakes. The 
THC content of the resin is 2 - 30 %. 
 
c. Cannabis oil of the resin 
 
Cannabis oil is extracted from hashish with an organic solvent or distillation 
technique out of hashish. The THC content in the oil is up to 65 %. 
 
d. Fatty oil of the seeds 
 
The fatty oil, extracted from the seeds, is very expedient for food use, since it 
contains a lot of essential fatty acids. Usually it does not contain THC. 
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2.1.1.4. Legislation for Cannabis preparations [21, 22] 
 
In almost all countries of the world, the production, possession, purchase, and 
import, as well as the trade and transfer of cannabis are legally forbidden. Excluded 
from these regulations and restrictions are the use of cannabis for research projects. 
Under certain conditions and upon request, pharmaceutical companies may be 
allowed to raise seeds of THC rich cannabis for research purposes. In most countries 
and with a few restrictions, the sale of seeds (also of THC rich sorts) is permitted. 
This applies also for scions, provided their THC content does not exceed the 
predetermined limits.  
 
Worldwide, the use of natural cannabis products for medical purposes is practically 
not allowed. In contrast, drugs containing synthetic cannabinoides like MarinolTM are 
often exempt from these restrictions. Synthetic products, however, have a 
disadvantage: they do not contain a well-balanced combination of active substances 
which can be found in the natural hemp plant. Patients having consumed natural 
cannabinois for their medical therapy report more side-effects after the administration 
of synthetic cannabis preparations [4, 5]. It was speculated that this could particularly 
be the result of the absence of cannabidiol (CBD) in the synthetic product [4]. 
 
The United States Food and Drug Administration (FDA) approved MarinolTM to treat 
nausea and vomiting associated with cancer chemotherapy in patients who have 
failed to respond adequately to conventional therapies. The FDA also approved 
MarinolTM to treat appetite loss associated with weight reduction in people with 
acquired immunodeficiency syndrome (AIDS). 
 
In Switzerland, all cannabis preparations underlay the legislation of narcotics and are 
listed in the category of the forbidden substances. MarinolTM is not registered. The 
Swiss Federal Office of Public Health (FOPH) can exempt cause if the 
cannabinoids/cannabis preparations are used for research projects or for a limited 
medical therapy (“compassionate use”). A special exemption for MarinolTM can be 
obtained if a person suffers from cancer, HIV, AIDS, multiple sclerosis or paraplegia. 
With this permission, the import of dronabinol capsules is allowed. 
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2.1.2. Cannabinoids 
 
2.1.2.1. ∆9-tetrahydrocannabinol (THC) 
 
2.1.2.1.1. Structure 
 
The structure of THC using two different numbering systems is presented in Figure 2. 
The common system resulting in ∆9-tetrahydrocannabinol is based on the 
dihydrobenzopyran-numbering according the IUPAC (International Union of Pure and 
Applied Chemistry) rules and the other, resulting in ∆1-tetrahydrocannabinol is based 
on the monoterpene-numbering. THC is the only biogenic, psychotropic substance 
without nitrogen in the structure. THC is psychotropic and pharmacologically active. 
 
O
H
OH
H
11
2
3
4
4a
1
6
6a 10b
8
7
9
10
10a
5 1'
2'
3'
4'
5'
A
B C
 
 
 
∆9-tetrahydrocannabinol 
Dihydrobenzopyran-numbering  
C21H30O2 
 
O
H
OH
H
7
4'
5'
6'
3'
6
5
1
2
A
B C
1'
8
9
3
4
2'
10
 
 
∆1-tetrahydrocannabinol 
Monoterpene-numbering 
C21H30O2 
 
Figure 2: Structure of THC 
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2.1.2.1.2. Physical and chemical data of THC 
 
Chemical and physical data of THC are presented in Table 1 [10, 23]. 
 
Table 1: Physical and chemical properties of THC, dronabinol respectively 
Systematic name  (-)-trans-Isomer of the ∆9-THC, (-)-∆9-trans-THC (dronabinol) 
Chemically: (6aR-trans)-6a, 7, 8, 10a-Tetrahydro-6,6,9-
trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol 
Synonym Dronabinol 
Molecular weight  314.5 
Molecular formula C21H30O2 
Boiling point  200 ° C 
Property to rotate plane polarised 
light  
[ ]20Dα  -150.5° (c = 0.53 in CHCl 3)  
UV max in ethanol  283 nm and 276 nm 
Solubility 
 
Highly insoluble in water (∼2.8 mg/L, 23 ° C) and 0.15 M NaCl 
 
(0.77 mg/L, 23 ° C) 
 
High solubility in ethanol, methanol 
Octanol:water partition coefficient  6,000:1 
pKa  10.6 
Stability  
 
Unstable in acidic solution ( t1/2 = 1h at pH 1.0, 55 ° C) 
 
Sensitive to light and heat 
Description  
 
Yellow resinous oil, sticky at room temperature, hardens upon 
 
refrigeration, without smell, bitter taste, high lipophilic 
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2.1.2.2. ∆9-tetrahydrocannabinolic acid A (THCA-A) [24] 
 
∆9-tetrahydrocannabinolic acid A (THCA-A) (Figure 3) is the precursor of THC in 
hemp plants. During smoking, the non-psychoactive and pharmacologically inactive 
THCA-A is converted to THC, the main psychoactive component of marijuana and 
hashish. In Cannabis sativa L., 95% of THC consists of its precursor THCA-A [25]. 
The decarboxylation of THC acids to the corresponding phenols (Figure 3) occurs 
readily over time, upon heating, or under alkaline conditions. 
 
 
Figure 3: Mechanism of the decarboxylation of THCA-A to THC 
 
2.1.2.3. Cannabidiol (CBD) 
 
After THC, CBD (Figure 4) is the next most abundant cannabinoid substance that 
occurs in the blood and urine following ingestion of hashish, marijuana or cannabis. 
According to recent results [26, 27], the carboxylated precursors used in the 
biosynthesis of CBD and THC are both directly derived from cannabigerolic acid. The 
existence of the postulated enzyme CBD-cyclase catalysing the synthesis of THC via 
CBD has not been experimentally confirmed. The CBD/THC ratio is mainly 
dependent on the genetic background of the individual plant. There is some evidence 
that CBD is devoid of psychotropic actions and may even antagonise the 
psychotropic effects of THC [4]. Evidence emerged that CBD partially inhibits the 
CYP2C9-catalysed hydroxylation of THC to the psychotropically active 11-OH-THC. 
The probability for this inhibition is particularly high for oral intake because THC and 
CBD attain relatively high concentrations in the liver and in addition there is a high 
first-pass metabolism of THC [1, 28]. CBD does not bind to the known cannabinoid 
receptors and its mechanism of action is presently unknown [29]. 
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Figure 4: Cannabidiol 
 
2.1.2.4. Cannabidiol acid (CBD-A) 
 
O
OH
H
COOH
 
 
Figure 5: Cannabidiol acid 
 
CBD-A (Figure 5) is a non-psychotropic and antimicrobial substance [30]. 
Decarboxylation of CBD acid to the corresponding phenol occurs readily over time, 
under heating or alkaline conditions [31]. CBD-A decarboxylates to CBD that 
undergoes a cyclisation to THC (Figure 6). 
 
 
 
 
 
 
Figure 6: Decarboxylation of CBD-A to CBD and cyclisation to THC 
 
CBD-A CBD THC 
 Introduction - Biological Part   
 24 
2.1.2.5. The four cannabinoid types 
 
Cannabinoids have four types: the drug type, the inter type, the fibre type and the 
propylisomer type (Table 2). The main cannabinoids of the fibre type are CBD and 
CBD-A and those of the drug type are THC and THCA-A [32]. 
 
Table 2: The four cannabinoid types, modified from [32] 
TYPE NAME MAIN CANNABINOIDS PSYCHOACTIVITY 
I drug type THC/THCA-A ++ 
II inter typ THC/THCA-A, CBD/CBD-A ++ 
III fibre-/seed type CBD/CBD-A (+) 
IV propylisomer type ∆9-tetrahydrocannabi-varin/ 
-acid 
++ 
 
 
2.1.2.6. Dronabinol [10] 
 
Dronabinol is a synthetically produced THC. The structure of dronabinol is presented 
in Figure 7. dronabinol is a light yellow resinous oil that is sticky at room temperature 
and hardens upon refrigeration. dronabinol is insoluble in water and is formulated in 
sesame oil. It has a pKa of 10.6 and at pH 7.0 an octanol:water partition coefficient of 
6,000:1. MarinolTM for oral administration are round and soft gelatine capsules 
containing 2.5 mg, 5 mg or 10 mg dronabinol. The United States Food and Drug 
Administration (FDA) approved MarinolTM to treat nausea and vomiting associated 
with cancer chemotherapy in patients who have failed to respond adequately to 
conventional therapiess. The FDA also approved MarinolTM to treat appetite loss 
associated with weight reduction in people with acquired immunodeficiency 
syndrome (AIDS). 
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Figure 7: Dronabinol (MarinolTM) C21H30O2 
 
2.1.3. Pharmacological and toxicological effects of THC 
 
2.1.3.1. Pharmacokinetics 
 
a. Absorption and distribution of THC [15, 33-35] 
 
THC is rapidly absorbed after the inhalation of cannabis smoke. Rate of absorption 
depends on the inhalation technique and smoking frequency, resulting in very 
variable bioavailabilities (10-20%). The absorption after oral administration is more 
erratic because of a variable degradation of the drug by stomach acids and the 
extensive liver first-pass metabolism. Cannabinoids dissolved in a lipophilic vehicle 
like sesame oil can increase the absorption up to 95%. Due to the extensive liver 
first-pass metabolism, the measured bioavailability is very low (10-20%) [10]. THC 
administered as a prodrug (THC-hemisuccinate) in suppositories shows more 
constant- and about two-fold higher bioavailabilities compared to an oral application. 
Cannabinoids rapidly penetrate into the tissues (liver, heart, lung, gut, kidney, spleen, 
mammary gland, placenta, adrenal cortex, thyroid, pituitary gland, fat and lower 
concentrations in brain, testis and foetus) because of their high lipophilicity. 
Therefore, the distribution volume is about 10 L/kg. THC is strongly bound to plasma 
proteins (~97%). About 60% is bound to lipoproteins (the low-density fraction), about 
9% to blood cells and the rest to albumin. The THC metabolite 11-hydroxy-∆9-THC 
(11-OH-THC) is even more strongly bound (~99%). 
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b. Metabolism of THC [15, 28, 35, 36] 
 
About 100 metabolites have been identified for THC so far. All cannabinoids are 
good substrates of cytochrome P450. The hydroxylation sides of THC are at C11 and 
C8 as well as at all positions of the alkyl side-chain. The preferred hydroxylation site 
in man is C11. It has been shown that cytochrome P450 isoenzyme 2C9 catalysis the 
formation of the psychoactive 11-OH-THC metabolite of THC and that cytochrome 
P450 3A is responsible for the hydroxylation at the 8β-position [37, 38]. Many of the 
hydroxyl groups undergo further oxidation after the hydroxylation. Carboxylic groups 
at C11 and C5’ (alkyl side-chain) are formed. 11-OH-THC is further oxidised, 
probably by alcohol dehydrogenase and of microsomal alcohol oxygenase, to the 
intermediate aldehyde 11-oxo-THC followed by oxidation to 11-nor-9-carboxy-THC 
catalysed by a microsomal aldehyde oxygenase, a member of the CYP2C subfamily 
[37, 39, 40]. After glucuronidation of the carboxy group, the THC-COOH is the main 
metabolite excreted and found in urine [28]. Carbon atoms from the alkyl side-chain 
get lost after β-oxidation and related reactions of the C5’-acid. The predominant 
phase II metabolite of THC is the O-ester-glucuronide of THC-COOH. The formation 
of conjugates with long-chain fatty acids is another possible pathway. Although it is a 
phase II reaction, the lipophilicity is rather increased than decreased. It is possible 
that these conjugates with long-chain fatty acids may be retained within tissues for 
considerable periods of time because they are membrane constituents resembling 
compounds. Figure 8 shows the main metabolic pathways for THC. The possible 
sites for the primary oxidation of THC are presented in Figure 9.  
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Figure 8: Main metabolic pathways for THC [24, 28, 41]
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Figure 9: Sites for primary oxidation of THC 
 
c. Excretion [15, 35, 36] 
 
Elimination of THC from the plasma is rather slow because of the limited re-diffusion 
of THC from body fat and other tissues into the blood. The results of this 
phenomenon are low plasma levels. The literature describes very variable half-life 
periods from 1 to 4 days. The absolute elimination time could require up to five 
weeks. THC metabolites are excreted in urine (~20%) and faeces (~80%). The 
distinctive enterohepatic cycle is another reason for the slow elimination. Most 
urinary metabolites are acids. The major metabolites found in urine are THC-COOH 
and THC-COOH-glucuronide. Normalised to the drug creatinine ratio, THC-COOH 
and its glucuronide are used for the detection and monitoring of drug abuse. 
 
2.1.3.2. Pharmacodynamics 
 
a. The endogenous cannabinoid system, cannabinoid receptors 
[42, 43] and the structure-activity relationship (SAR) at the 
cannabinoid (CB) receptor [44, 45]. 
 
Two cannabinoid receptors are known in mammalian tissues. Both receptors are 
coupled to their effector systems through Gi/o proteins. CB1 receptors are expressed 
in the spinal cord, in the brain and in certain peripheral tissues. It is supposed that 
some central and peripheral CB1 receptors, located at nerve terminals, modulate 
neurotransmitter release. CB2 receptors were found in immune tissues (e.g. 
leukocytes, spleen and tonsils). In the nineties, the discovery of CB1 and CB2 
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receptors was followed by the detection of endogenous cannabinoid-receptor 
ligands. Arachidonoylethanolamide (anandamide) and 2-Arachidonoylglycerol (2-AG) 
are the most important ones. The human body synthesises anandamide from N-
arachidonoyl-phosphatidylethanolamine, which is itself made by transferring 
arachidonic acid from phosphatidylcholine (PC) to the free amine of 
phosphatidylethanolamine (PE). It is supposed that both agonists can act as 
neuromodulators or neurotransmitters. Anandamide and methanandamide activate 
vanilloid receptors on sensoric neurons [46]. Anandamide is an endogenous ligand 
for vanilloid receptors. Therefore, the vanilloid receptors represent possibly a 
cannabinoid CB3 receptor [46]. The cannabinoid receptors and their endogenous 
ligands are denoted as “the endogenous cannabinoid system” or “endocannabinoid 
system”. The endocannabinoid system is important for the regulation of processes in 
the central nervous system (neurotransmitter release). Furthermore, it regulates 
neurotransmitter release/action of autonomic and sensory fibres and it controls 
gastrointestinal, immunological and cardiovascular performance in the periphery. The 
links to neurotransmitter systems and all these functions are not yet fully understood. 
For both CB receptors, several selective synthetic agonists and antagonists have 
been synthesised. They are used for basic and clinical research. Possible 
biochemical pathways for THC and cannabinoids are presented in Figure 10. 
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Figure 10: THC and cannabinoid effects on phospholipids- and arachidonic acid-dependent 
biochemical processes. THC binds to a G-protein receptor which affects adenylatcyclase-dependent 
processes (Reproduced after [47]). 
 
The binding of THC to the CB1 receptor demands different essential structure-activity 
relationships. In most active cannabinoids, the dihydrobenzopyran-type structure with 
a hydroxylgroup at C1 and an alkyl group at C3 is present. The activity at the CB1 
receptor gets lost as a result of a pyranring opening (forming cannabidiol-type 
compounds). The alkylic side chain with at least 5 carbon atoms at position C3 is of 
considerable importance: elongation and branching results in potentiation. It is 
essential that the phenolic group at the C1-position is free. The stereochemical trans-
link of the two rings A and B at position C6a and C10a is important for the activity. 
 
2.1.4. Therapeutic potential of THC [48] 
 
As described in chapter 2.1.2.6. THC or cannabis preparations are well established 
in the therapy of nausea and vomiting associated with cancer and for appetite loss 
associated with weight reduction in people with AIDS as well as in Alzheimer’s 
disease patients. MarinolTM is registered and used in the USA for these indications. It 
was shown in recent studies that THC or cannabis preparations have a promising 
potential to combat spasticity, moving disorders and pain in patients suffering from 
multiple sclerosis. Some case reports show THC effects against pruritus, allergies, 
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inflammations, infections, depressions, epilepsy, anxiety, withdrawal syndromes and 
addiction. Furthermore, THC lowers intraocular pressure in glaucoma and is anti-
asthmatic. Worthwhile research areas for a possible treatment with THC are high 
blood pressure, autoimmune diseases, neuroprotection and cancer fever [7, 49, 50]. 
 
2.1.5. Toxicology and adverse effects of THC 
 
a. Acute toxicology of THC [51] 
 
No deaths directly linked to toxic somatic effects of cannabis have been reported so 
far in human. With an oral LD50 dose in rats of 800 to 1900 mg/kg the acute toxicity of 
THC is very low. There were no cases of death due to toxicity following the maximum 
oral THC dose in dogs (up to 3000 mg/kg administered) and monkeys (up to 9000 
mg/kg). Nevertheless, acute adverse effects after cannabis consumption are 
reported. Instead of a pleasant and relaxing feeling, dysphoric reactions sometimes 
accompanied with panic attacks and fear of death are reported. The ability to drive a 
car and cognitive functions like attention, reaction and memory are impaired. Further 
reported effects are sleepiness, dizziness, confusion and mental clouding. 
 
b. Long-term toxicology of THC [51, 52] 
 
The main described chronic effect after cannabis smoke inhalation (“joint”) is the 
destruction of the mucous membrane in consequence of pyrolysis products. It is 
evident that the cognitive functions and memory are decreased in heavy cannabis 
users. Cannabis can cause “temporal disintegration”. This term is described as a 
difficulty in regaining, coordinating and serially indexing memories. Perceptions and 
expectations that are relevant to the attainment of some goals are limited [53]. 
Vulnerable persons are at risk of a latent schizophrenia after cannabis consumption. 
The incidence of schizophrenia is not increased. Contradictory results are described 
about fertility and long-term toxic effects of the immune and endocrine system. No 
indication of an impairment of these functions is described in humans. As a result of 
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a cannabis consuming pregnant woman, the cerebral functions in the foetus can be 
impaired because of disturbances in the development of subtle cerebral functions 
[51, 52]. 
 
2.1.6. THC tolerance [54] 
 
Frequent cannabis use quickly leads to a tolerance development. Tolerance is 
attributed to pharmacodynamic changes, probably based on receptor down 
regulation or receptor desensitisation. It can also be attributed to pharmacokinetic 
parameters like changes in absorption and metabolism, for example, modified 
biotransformation activities with regard to cytochrome P450. Mild withdrawal 
syndromes are reported by heavy chronic cannabis consumers after they cease 
taking the drug. The described symptoms are nervous agitation, hyperhidrosis and 
lack of appetite. The risk for cannabis abuse in the therapeutic context is low, the 
dependence is mainly a psychological and not a somatic effect. 
 
2.1.7. Somatic adverse effects of THC [51] 
 
Acute atropine-like adverse effects such as increased heart rate, hyposalivation 
reddening of the eyes and orthostatic hypotension, can occur after cannabis 
consumption. The risk of infections in the eyes and of the upper respiratory tract is 
increased by a decrease of lacrimation and hyposalivation. Nausea, headache and 
vomiting occur rarely. 
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2.2. Technical part 
 
2.2.1. Urine drug testing and sample preparation 
 
2.2.1.1. Specimen matrices and urine drug testing 
 
Laboratory analyses of cannabinoids or other drugs have forensic, criminal and 
clinical utilisations. Urine, blood, saliva and hair are the common matrices for the 
detection of drugs. The collection of urine is easy. The drugs and their metabolites 
found in urine can be detected for a longer time frame after application compared to 
blood or saliva [55]. A hydrolysation procedure of the urine before the analysis to 
convert drug conjugates (glucuronides) to their free metabolites is advantageous for 
several analytical techniques. The rate of false positive or false negative results 
should be minimised in an analytical method. To achieve this objective, it is 
necessary to identify presumably positive specimens in a screening test. The 
principle of an immunoassay test is the use of antibodies binding to the drug. The 
selectivity is limited depending on the antibodies specificity in the immunoassay. 
False positive results can be caused if chemically similar structured substances of 
the assumed drug interfere with the test. A sample concentration below the 
accepted threshold or a dilution or adulteration of the sample to obscure the 
presence of a drug can lead to false negative results. Unfortunately, often in a 
screening test cross-reactive substances have to be considered [56]. Therefore, 
preliminary positive immunoassay results have to be confirmed by a second, more 
specific analysis method like mass spectrometry (MS) [55, 57].  
 
Urine contains creatinine, a metabolic waste product removed from muscular 
tissue. It is filtered from the blood by the kidneys and excreted in the urine, nearly 
not secreted and not reabsorbed in the tubular system. This is the reason why the 
measurement of creatinine in blood and urine serve as parameters for the 
calculation of the glomerular filtration rate. Creatinine is excreted nearly constantly 
during the day, so it serves as a normalisation factor for urinary excretion of other 
substances. For measuring drugs excreted into the urine, the drug/creatinine ratio 
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is therefore often used as a normalisation factor if different measurements have to 
be compared [58]. 
 
2.2.1.2. Sample preparation 
 
a. Liquid-liquid- and solid phase extraction 
 
A pre-analytical isolation procedure to separate drugs from interfering substances in 
biological matrices is required in HPLC and LC-MS/MS. The main preparation 
techniques are liquid-liquid extraction (LLE) and solid phase extraction (SPE). These 
methods can be applied manually and automated. The manual (off-line) sample 
preparation can be adapted to every analysis but it is more time consuming than an 
automated (on-line) method. In an on-line method, the machine pipettes and washes 
the sample on its own. It is fast and easy. In LLE, the separation must be conducted 
at a pH at which the analyte is uncharged. Acidic drugs need an acidified aqueous 
phase, basic drugs a basified one. LLE is difficult to automate. It is time consuming 
and wastes large amounts of organic solvents compared to SPE. The organic 
solvents are often toxic and expensive. Solid-phase extraction (SPE) uses both a 
solid phase and a liquid phase to isolate an analyte from a solution. The general 
procedure is to load a solution onto the SPE phase, wash away undesired 
components, and then wash off the desired analytes with another solvent into a 
collection tube. SPE is based on intermolecular forces (hydrogen bonding, dipole-
dipole forces, ionic interactions, Van der Waal forces) of the analyte with the sorbent, 
the liquid phase and the sample matrix. 
 
b. Reversed-phase SPE 
 
Reversed-phase (RP) SPE chromatography separates organic solutes from a polar 
phase (generally aqueous) into a non-polar phase. The stationary phase of a RP 
SPE cartridge is derivatised with hydrocarbon chains. The affinity of the solute to the 
sorbent depends upon its hydrophobicity. The analyte is eluted with an organic 
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solvent (like acetonitrile, ethyl acetate or methanol) which disrupts the interaction of 
the analyte and the stationary phase [59]. The most common RP sorbents for SPE 
are chemically bonded silica phases [60-62]. Most widely used bonded phases are 
C8 and C18 sorbents [63]. 
 
c. Ion exchange SPE 
 
The separation in ion exchange sorbents is based on electrostatic interactions 
between the analyte of interest and the positively charged groups on the stationary 
phase. A pH at which the stationary phase and the sample are charged is needed for 
the ion exchange. Anion exchange sorbents are derivatised with positively or 
negatively charged functional groups. These sorbents retain negatively charged 
anions like acids. Strong anion exchange sorbents contain quaternary ammonium 
groups. They are permanently positive charged in aqueous solutions. Cation 
exchange sorbents are derivatised with negatively functional groups. They retain 
positively charged cations like bases. Strong cation exchange sorbents contain 
aliphatic sulfonic acid groups. They are always negatively charged in aqueous 
solutions [59]. 
 
d. Certify II cartridges for the extraction of THC-COOH 
 
Certify II (Varian) are bonded silica mixed mode sorbent solid phase extraction 
cartridges used to extract acidic drugs like THC-COOH. Since this drug contains an 
acidic functional group, clean-up from urine samples can be optimised by using an 
anion exchange sorbent. Retention of acidic drugs on Certify II is initially achieved by 
non-polar interactions on the hydrophobic portion of the sorbent. Polar interferences 
can then be washed away with a basic buffer. This wash step also ensures that the 
COOH functional group is deprotonated, forming COO-, which can then be retained 
on the anion exchange portion of the Certify II sorbent. After briefly drying the 
cartridge, non-polar and basic drugs can be removed with a non-polar solvent. 
Finally, the THC-COOH can be recovered by elution with a non-polar acidic solvent 
such as acetonitrile with 2% ammonia. [64]. 
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2.2.2. LC-MS/MS conditions 
 
2.2.2.1. Photo Diode Array (PDA) 
 
The utilisation of a photo diode array detector allows the measurement of the 
absorbance of a component over the complete wavelength range at the same time. 
The photodiodes are arranged in parallel. Each array measures a small spectral area 
[65]. Photo diode array ultraviolet detectors record the absorbance of compounds at 
a wavelength range of 200-400 nm as they pass through the detector flow cell, 
allowing the on-line acquisition of UV spectra.  
 
2.2.2.2. Overview of a LC-MS system 
 
The coupling of LC and MS was a breakthrough in analytical technology. It is an 
alternative and complement to GC-MS [66]. The combination of selective and 
sensitive LC-systems with mass spectrometers and a simple sample preparation for 
LC may be the “gold standard” for bioanalytical application. The development of a 
chromatographic method is usually a compromise between desired resolution and 
analysis time. The reduction in the stationary phase particle size can result in the 
benefit to the chromatographic process [67]. The sample is injected by an injection 
port (e.g. autosampler) in the mobile phase stream delivered by the high-pressure 
pump and transported through the column where the separation takes place [68]. A 
gradient running solvent is normally used in a qualitative drug screening for the 
analysis of the large diversity of substances. For quantitative LC analyses of 
compounds identified by screening, sometimes it can be more efficient to use 
isocratic chromatography. 
 
After the separation, the different, separated substances passes the MS detector 
system. It consists of an API source, an ion transfer capillary, tube lens and skimmer, 
ion optics, mass analyser and ion detection system. The sample ionisation takes 
place in the API source. The produced cations or anions are transmitted by the ion 
optics into the mass analyser. Selected ions are ejected from the mass analyser and 
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reach the ion detection system where they produce a signal. In Figure 11 a 
schematic drawing of a liquid-chromatography mass spectrometer system is shown. 
 
 
 
 
 
 
 
Figure 11: Schematic drawing of a liquid-chromatography mass spectrometer system (Reproduced 
after [69]). 
 
2.2.2.3. API interfaces 
 
The challenge of coupling two systems like LC and MS, one operating in liquid phase 
and the other in high vacuum, has been overcome by creating dedicated interfaces. 
Today the most widely used interfaces are electrospray ionisation (ESI) and 
atmospheric pressure chemical ionisation (APCI). APCI is generally regarded as the 
more robust ionisation method. It is less susceptible to signal suppression from co-
eluting matrix components [70, 71] or to changes in variables such as changes in 
buffer and buffer strength. ESI is the softer and more versatile of the two methods 
enabling it to ionise very polar/non volatile molecules [70]. LC-MS interfaces remove 
the mobile phase and ionise the analyte. The collision-induced dissociation is 
followed by a thorough fragmentation (MSMS) of the compounds. 
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2.2.2.4. Atmospheric pressure chemical ionisation (APCI) and electro-
spray ionisation (ESI) 
 
APCI is suited for the analysis of molecules with a molecular weight up to 2’000 
atomic mass units (amu) with a medium polarity and some volatility. The pH of the 
analyte in the gas phase and the solvent vapour play an important role in the APCI 
process because it works in the gas phase. The flow rate of solvent in APCI mode is 
typically high with 0.2 - 2 ml/min [72]. The APCI nozzle vaporises the sample solution 
in a high temperature (~500 ° C). A needle is located near the end of the t ube. A high 
voltage is applied to the corona discharge needle. Electrons are produced (Figure 
12). The electrons react with the liquid phase and the nitrogen gas. N2 is delivered by 
the sheath and auxiliary gas. Reagent ions are formed through a series of chemical 
reactions. The reagent ions react with the sample molecules. The charge is 
transferred to the sample molecules which get ionised. 
 
 
Figure 12: Atmospheric pressure chemical ionisation 
 
Heat-labile compounds or high molecular weight compounds, which were previously 
not suitable for mass analysis, can be analysed by the soft ESI method. ESI can 
analyse any polar compounds which generate ions in solution. ESI allows the 
analysis of big molecules (>100'000 amu) like peptides and proteins due to the 
multiple charging. The flow rate of solvent in ESI mode is ranging from 1 to 1000 
µl/min. The eluent from the LC system is sprayed through a capillary into the ESI 
source region. It is nebulised in a fine mist of droplets by a pneumatically assisted 
gas stream and a high temperature (Figure 13). The droplets are electrically charged 
at their surface when a capillary voltage is applied. Solvent evaporates from the 
droplets. The electrical charge density increases up to a critical point known as the 
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Rayleigh stability limit (the electrostatic repulsion is greater than the surface tension 
[73]). At this point, the droplet-clusters divide into smaller droplets [74, 75]. This 
mechanism is repeated several times. Sample ions are generated out of the cluster 
ions and move towards the entrance of the mass spectrometer by an electrical field. 
The ESI process is affected by droplet size, liquid surface tension, solvent volatility, 
surface charge and ion solvation strength. A good ESI process is prevented by large 
droplets with high surface tension, low volatility, strong ion solvation, low surface 
charge and high conductivity [75]. 
 
 
Figure 13: Electrospray ionisation 
 
APCI and ESI work in the positive and negative ion polarity mode. A positive applied 
voltage generates cations, a negative one, anions. The ion-positive mode produces a 
stronger ion current for most molecules, especially for those with one or more basic 
(nitrogen) atoms. An exception to this rule are molecules with acidic sites (carboxylic 
acids or acidic alcohols). They produce strong negative ions. In general, more 
positive ions are produced but negative ion polarity can be more specific. The 
negative ion polarity mode often has less chemical noise compared to the positive 
one.  
 
2.2.2.5. Ion transfer capillary and ion optics 
 
The heatable (150-200° C) ion transfer capillary as sists in desolvating the produced 
ions on their way to the mass analyser. A decreasing pressure gradient and 
electrostatic forces transport the ions to the skimmer region. First, they enter the tube 
lens. The ions are focused towards the skimmer through a dependent potential in the 
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tube lens. A collision with the residual solvent and with gas molecules can occur if 
the tube lens offset voltage is high. Fragments can be produced by this ion source 
collision induced dissociation (CID). The duty of the skimmer is to reduce the number 
of neutral molecules and large charged particles, because they would create detector 
noise. The produced cations or anions are transmitted from the API source by the ion 
optics (in our apparatus octapoles) into the mass analyser. The ion stream coming 
from the source is directed and focused by magnetic fields. 
 
2.2.2.6. Mass analysis, detection modes and mass analysers 
 
Mass analysis of ionised substances is performed by using one (LC-MS) or two mass 
analysers (LC-MS/MS). The most common instruments are ion traps and 
quadrupoles, less frequently sector field and time-of-flight instruments (TOF) are 
used. 
 
Quadrupoles and ion trap mass-analysers can operate in the full scan mode or in the 
more sensitive selected-ion monitoring mode (SIM). They detect positive and 
negative ions. The modes can be combined in parent-ion scanning (scan mode in the 
first, SIM in the second analyser), daughter-ion scanning (DIS; SIM in the first, scan 
mode in the second analyser), constant neutral-loss scanning (CNLS; scan mode in 
both analysers) or selected-reaction monitoring (SRM; SIM in both analysers). The 
most common mode is the DIS, where a specific precursor is selected in the first 
quadrupole, fragmented in the collision cell and the products subsequently monitored 
in the second quadrupole. Another mode is multiple-reaction monitoring (MRM). It is 
the most powerful technique for the quantification of small amounts of analyte in 
complex matrices [76, 77]. The use of these scan modes is important in the analysis 
of drug metabolites which have a similar fragmentation behaviour and produce 
common fragment ions. 
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Mass analysing can be divided in four steps: Ion storage, ion isolation (SIM, SRM, 
and MS/MS full scan), collision induced dissociation (SRM and MS/MS full scan) and 
ion scan out. 
 
The use of CID in a quadrupole, which is the most common ion activation method, 
was an important step in the development of LC-MS [78, 79]. The low-energy 
collisions are used in LC-MS/MS. The instrument consists of a first quadrupole, a 
collision cell and a second quadrupole for the production of fragment ions (Figure 
14). In LC-MS/MS, the production of fragment ions is distinct from the ionisation step. 
The precursor and product ions are characterised independently by their m/z ratios 
[80]. Product ions are built by single or multiple collisions of the precursor ions with 
neutral gas molecules in the collision cell. Collisions between precursor ions and a 
neutral target gas like N2 or Ar are followed by an increase in internal energy of the 
ion. A decomposition is induced which provides structurally informative fragments 
(product ions). 
 
The linear quadrupole mass analyser is a mass filter. It consists of four hyperbolic or 
circular rods, which are placed parallel in a radial array [81]. A radiofrequency- and a 
direct current offset voltage are applied to the rods. An electrical field is produced 
that guides the desired ions along the axis of the quadrupole. The ions with an 
unwanted m/z ratio collide with the four square rods. The offset voltage is negative 
for positive ions and positive for negative ions during the ion transmission. The triple 
quadrupole is the most common mass spectrometer. 
 
 
 
Figure 14: Scheme of a mass analyser in tandem mass spectrometry (Reproduced after Sciex 
instruction). 
 
Precursor ion Collision with 
N2 or Ar 
  Quadrupole 1             Collision cell             Quadrupole 2 
Product ions 
(Fragments) 
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The essential parts of an ion trap mass-analyser are three electrodes. The entrance 
and exit endcap electrodes have a small hole in their centre. The passage of ions 
into and out of the mass analyser cavity is possible through these holes. The 
voltages applied to the endcap electrodes are equal in amplitude but are 180 ° C out 
of phase to one another. The trapment, fragmentation and ejection of ions according 
to their mass-to-charge ratios are possible through various alternating current 
voltages applied to the ring and endcap electrodes. A radiofrequency voltage is 
applied to the ring electrode. It produces a three dimensional quadrupole field within 
the mass analyser cavity. An ionic movement in the axial (towards the endcaps) and 
radial (from the ring electrode towards the centre) directions is driven. The stream is 
essential for the ions to remain trapped. The system produces an m/z dependent 
instability during the ion scan out. The ions are ejected from the mass analyser in the 
axial direction. When the radiofrequency applied to the endcaps equals the 
resonance frequency of a trapped ion, the ion gains kinetic energy and is ejected. 
During the CID in an ion trap, a voltage is applied to the endcap electrodes to 
fragment precursor ions into product ions. This voltage is not strong enough to eject 
an ion from the mass analyser but ion motion in the axial direction is enhanced and 
the ion gains kinetic energy. After many collisions with helium gas in the mass 
analyser cavity, the ions are energetic enough to dissociate into product ions. 
 
2.2.2.7. Ion detection system 
 
A conversion dynode and a channel electron multiplier are the main part of the ion 
detection system. A +15 kV potential for negative ion detection or a -15 kV one for 
positive ion detection is applied to the conversion dynode [82]. When an ion strikes 
the surface of the conversion dynode, one or more secondary particles are produced. 
These secondary particles can include positive or negative ions, electrons and 
neutrons. When positive ions strike a negatively charged conversion dynode, the 
secondary particles of interest are negative ions and electrons. The result of negative 
ions are positive secondary particles. The secondary particles are focused by the 
curved surface of the conversion dynode and are accelerated by a voltage gradient 
into the electron multiplier [82]. Secondary particles from the conversion dynode 
strike the inner walls of the electron multiplier with sufficient energy to eject electrons. 
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The ejected electrons are accelerated further into the cathode, drawn by the 
increasingly positive gradient. Due to the funnel shape electrons do not travel far. 
They strike the surface again, thereby causing the emission of more electrons. A 
cascade of electrons is created finally resulting in a measurable current. The current 
is proportional to the number of secondary particles striking the cathode [82]. 
 
2.2.2.8. Vacuum System 
 
Mass analysis, analyte ionisation and detection take place in a high-vacuum system. 
This is necessary to avoid a collision of the produced ions with molecules (N2, O2) 
passing from the API stack to the ion detection system at normal pressure. The 
vacuum system evacuates the region around the API stack, ion optics, mass 
analyser and ion detection system. High vacuum levels cause reduced sensitivity and 
reduced lifetime of the electron multiplier. A forepump with a pressure of 
approximately 1.33 mbar establishes the vacuum necessary for the proper operation 
of the turbomolecular pump. The vacuum in the API region is usually 1020 mbar and 
2.67x10-5 mbar in the analyser region [82]. 
 
2.2.2.9. Adduct formation 
 
Adduct formation frequently occurs in the ionisation process in MS. The molecule 
ionisation usually results in deprotonated (M-H)- ions in the negative mode and in 
protonated (M+H)+ ones in the positive ionisation mode. Parallel to the ionisation of 
analyte molecules, ionisation with solvent molecules can occur. Adduct formations 
like (M+Na)+, (M+K)+ or (M+NH4)+ are reported [83, 84]. Addition of ammonium 
results in (M+NH4)+. The first step in fragmentation is the loss of neutral NH3. The 
latter can then fragment further. The adduct formation process is not reproducible. 
Sodium adduct ions are quite stable and yield less fragments. Adduct formation 
should be included in the validation procedure of a LC-MS method. 
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2.2.2.10. Retention time 
 
Due to changes in the gradual stationary phase or between different batches of 
columns with nominally identical packing material, the retention time of a substance 
is not constant over a period of time. Relative retention time or retention index (RI) 
has been shown to be an advantageous method to correct this variability [85]. RI is 
based on the relationship between a substance’s retention time and that of a 
reference compound.  
 
2.2.3. Method validation, GLP and SOP 
 
New analytical methods, to be used in forensic and/or clinical toxicology require 
careful method development followed by a thorough validation of the final method in 
order to generate reproducible and reliable data. Reliable analytical data is a 
prerequisite for correct interpretation of toxicological findings in the evaluation of 
scientific studies, as well as in daily routine work [86]. The analytical laboratory 
conducting pharmacology/toxicology and other preclinical studies for regulatory 
submissions should adhere to FDA’s Good Laboratory Practice guidelines (GLP). A 
set of written standard operating procedures (SOP) should be compiled in the 
analytical laboratory to ensure a complete system of quality control and assurance. 
The fundamental parameters of a method validation should include the following: 
 
2.2.3.1. Selectivity 
 
Selectivity is defined as “the ability of the bioanalytical method to measure 
unequivocally and to differentiate the analyte(s) in the presence of components, 
which may be expected to be present. Typically, these might include metabolites, 
impurities, matrix components, etc.” [86]. Method selectivity is established by proof of 
the lack of response by analysing blank matrices from different lots [86-88]. Signals 
interfering with the signal of an analyte or an internal standard must be avoided. 
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2.2.3.2. Calibration model (linearity) 
 
The relationship between the concentration ratios of an analyte in the sample versus 
the corresponding internal standard must be investigated. Calibrators must cover the 
whole calibration range and should be matrix based. A minimum of five to eight 
concentration levels is required as well as a blank and a zero sample [87, 88]. 
 
2.2.3.3. Accuracy, precision and recovery 
 
The accuracy of an analytical method compares the closeness of mean test results 
obtained by the method to the true value (concentration) of the analyte. Accuracy is 
determined by replicate analysis of samples containing known amounts of the 
analyte and should be measured using a minimum of five determinations per 
concentration. The mean value should be within 15% of the actual value except at 
LLOQ, where it should not deviate by more than 20% (own definition). The deviation 
of the mean from the true value serves as the measure of accuracy [89]. The 
precision of an analytical method is defined as the amount of scatter in the results 
obtained from multiple analyses of a homogeneous sample. The exact sample and 
standard preparation procedures that will be used in the final method must be used in 
the precision study. Instrument precision or injection repeatability is the first type of 
precision study [90]. With 10 injections of one sample solution the performance of the 
chromatographic instrument is tested. The second type is repeatability or intra-assay 
precision [91]. The data is obtained by repeatedly analysing, in one laboratory on one 
day, aliquots of a homogeneous sample. The inter-assay precision describes the 
sample aliquots measured on different days. Intermediate precision is the third 
precision test obtained when the assay is performed by multiple analysts, using 
multiple instruments, on multiple days, in one laboratory. Different sources of 
reagents and multiple lots of columns should also be included in this study [91]. The 
last type of precision study, reproducibility, is determined by testing homogeneous 
samples in multiple laboratories, often as part of inter-laboratory cross-over studies 
[91]. 
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The recovery is the detector response obtained from an amount of the analyte added 
to and extracted from the biological matrix, compared to the detector response 
obtained for the true concentration of the pure authentic standard. Recovery of the 
analyte need not to be 100%, but the extent of recovery of an analyte and of the 
internal standard should be consistent, precise and reproducible. Recovery 
experiments should be performed by comparing the analytical results for extracted 
samples at three concentrations (low, medium, high) with un-extracted standards that 
represent 100% recovery [89]. 
 
2.2.3.4. Range of measurement (LLOQ, LLOD) 
 
The lower limit of quantification (LLOQ) is defined as the lowest amount of an analyte 
in a sample that can be quantitatively determined with suitable precision and 
accuracy (bias) [87]. The acceptance criteria for both parameters at LLOQ are 20% 
relative standard deviation for precision and ± 20% for bias [87]. With a signal-to-
noise ratio a LLOQ can be estimated as well. It should be ≥ 10. The upper limit of 
quantification (ULOQ) is the highest calibration standard that can be quantified with 
fulfilled acceptable precision and accuracy (bias). The limit of detection (LLOD) is 
defined as the lowest analyte concentration that can be detected. The LLOD is 
usually estimated at a signal-to-noise ration of 3:1. 
 
2.2.3.5. Stability 
 
Drug stability in a biological fluid is a function of the storage conditions, the chemical 
properties of the drug, the matrix and the container system. Stability procedures 
should evaluate the stability of the analytes during sample collection, handling and 
storage, as well as after going through freeze-thaw cycles and the analytical process. 
Conditions used in stability experiments should reflect situations likely to be 
encountered during actual sample handling and analysis [89]. 
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2.2.3.6. Matrix effect 
 
2.2.3.6.1. Matrix effect in mass spectrometry 
 
The suppression or enhancement of analyte ionisation by co-eluting compounds is a 
well known phenomenon in LC-MS(-MS) analysis. It depends on the sample matrix, 
the sample preparation procedure, constituents of the mobile phase, the 
chromatographic separation and the ionisation type [71]. The precision, sensitivity 
and accuracy of an analytical procedure are affected by the ion suppression or 
enhancement [92]. 
 
Matrix effects are more pronounced with ESI than with APCI [71]. The ionisation 
process in ESI occurs in the liquid phase. The matrix compounds and molecules of 
interest stand in competition for access to the droplet surface and subsequent gas-
phase emission. The ionisation process can also be affected by a change of the 
properties of the surface tension and viscosity caused by matrix constituents [71]. 
Matrix effects also occur in APCI where the ionisation process is taking place in the 
gas phase. The non-volatile matrix compounds can co-precipitate with the analyte 
molecules [93]. 
 
Matrix effects are caused by the presence of less volatile compounds that can 
change the efficiency of droplet formation or droplet evaporation and affects the 
amount of charged ions in the gas phase that reaches the detector.  
 
2.2.3.6.2. Evaluation of matrix effects 
 
a. Evaluation after Matuszewski et al. 
 
A comprehensive strategy for the evaluation of matrix effects was recently published 
by Matuszewski et al. [94]. Three sets of samples are necessary. The principal 
approach involves determination of peak areas of analyte in three different sets of 
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samples. One consists of aqueous standard solutions (set A). For set B blank 
matrices are supplemented (after extraction) with the same amount of standards as 
used for set A. Set C consists of extracts of different blank matrices, supplemented 
with the same amount of standards but added before extraction. Recovery was 
calculated with the following formula: RE% = C/B x 100. Matrix effects were 
calculated with the formula: ME% = B/A x 100 and process efficiency with the 
formula: PE% = C/A x 100. For the calculation the resulting peak areas are needed. 
 
b. Post-column infusion after Bonfiglio et al. 
 
Bonfiglio et al. described another procedure to evaluate matrix effects. A solution of 
analyte is constantly infused into the eluent from the column via post-column tee 
connection using a syringe pump. The continuous post-column infusion leads to a 
constant signal in the detector, unless compounds that elute from the column 
suppress or enhance ionisation, which would lead to a decreased or increased 
detector response, respectively [86]. 
 
c. Influence of sample preparation and disturbing compounds 
 
Protein precipitation as a sample preparation method is not recommended because 
of its potential to cause matrix effects. On the one hand it was possible to remove the 
hydrophilic interfering compounds with SPE but on the other hand the hydrophobic 
interactions were increased. Matrix effects can be decreased by a reduced injection 
of matrix constituents. The injection of a smaller sample volume, a diluted sample or 
by applying more selective extraction techniques can help. Unfortunately, the 
separation in the liquid chromatographic system is limited by these steps. The use of 
a co-eluting internal standard like a labelled IS is recommended. The matrix effect on 
the analyte and on the internal standard is expected to be identical. Unfortunately, 
not every labelled standard is available and costs are often very expensive. There 
are compounds known to cause matrix effects like anticoagulants, dosing vehicles 
(polyethylenglycol, propylenglycol and cremophore), salts, fatty acids, triglycerides 
and constituents of sampling material (e.g. polymers) [95, 96].
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Abstract 
 
A novel high-performance liquid chromatographic separation method with tandem-
mass spectrometry detection was developed for the simultaneous determination of ∆ 
9-tetrahydrocannabinol (THC) and its major metabolites 11-hydroxy-∆9-
tetrahydrocannabinol (11-OH-THC) and 11-nor-∆9-tetrahydrocannabinol-9-carboxylic 
acid (THC-COOH) as well as the components cannabidiol (CBD) and cannabinol 
(CBN) in human EDTA-plasma and urine. Run time was 25 minutes. Lower limit of 
quantification was 0.2 ng/ml. The coefficients of variation of all inter- and intra-assay 
determinations were between 1.3 and 15.5%. The method was successfully applied 
to the determination of cannabinoids in human plasma and human urine after 
administration of ∆9-tetrahydrocannabinol or Cannabis sativa L. extracts.  
 
Keywords 
 
∆9-tetrahydrocannabinol; 11-hydroxy-∆9-tetrahydrocannabinol; 11-Nor ∆9-tetrahydro-
cannabinol-9-carboxylic acid; Cannabidiol; Cannabinol; Cannabinoids; LC-MS/MS; 
APCI; Human EDTA-plasma; Human urine  
 
1. Introduction 
 
After ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD) is the next most abundant 
cannabinoid substance that occurs in the blood and urine following ingestion of 
hashish, marijuana or cannabis. According to recent results [26, 27], the carboxylated 
precursors used in the biosynthesis of CBD and THC are both directly derived from 
cannabigerolic acid. The existence of the postulated enzyme CBD-cyclase catalysing 
the synthesis of THC via CBD has not been experimentally confirmed. The CBD/THC 
ratio is mainly dependent on the genetic background of the individual plant.  
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There is some evidence that CBD is devoid of psychotropic actions and may even 
antagonise the psychotropic effects of THC [4]. This is thought to occur by inhibition 
of the hydroxylation of THC to 11-OH-THC [1]. Cannabinoids are currently under 
clinical investigations because of the potential of proven sedative [97], anti-epileptic 
[98-101], anti-emetic- [102] and anti-inflammatory effects [103]. They may reduce 
intraocular pressure [104] and may have anxiolytic effects [105]. Psychic symptoms 
(such as acute and chronic psychosis and depression) have been observed after 
cannabinoid consumption [106, 107], especially after high doses. CBD does not bind 
to the known cannabinoid receptors, and its mechanism of action is unknown yet 
[29].  
 
To characterise the metabolic pattern of THC and its metabolites resulting from 
ingestion of cannabinoids, we have developed a sensitive and specific analytical 
method using LC-MS/MS and atmospheric pressure chemical ionisation (APCI). This 
method was used to characterise the metabolism of cannabinoids based on the 
source (extracts or pure substances) and route of administration (oral ingestion). 
Electrospray ionisation (ESI) methods often are more sensitive than APCI methods. 
However, for the actual method APCI was chosen because of less matrix effects. In 
addition, the lower limits of detection (LLODs) and lower limits of quantification 
(LLOQs) were low enough for the determination of THC and its metabolites in the 
provided study.  
 
Several methods are reported in the literature for the estimation of THC or its 
metabolites in plasma and urine by gas chromatography/mass spectrometry (GC/MS) 
after liquid/liquid or solid-phase extraction (SPE) and derivatisation [108-111]. Major 
disadvantages of these methods are the elaborate sample preparation and the need 
to use various derivatisation techniques for non-volatile and thermolabile compounds. 
Other reported chromatographic methods are high-performance liquid 
chromatography (HPLC) [108] with ultraviolet or electrochemical detection (UV, ED), 
and gas chromatography (GC) with electron capture, flame ionisation or nitrogen-
phosphorous detection (ECD, FID, NPD) [110]. Generally these methods lack either 
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specificity or sensitivity. Recently, LC/MS or LC-MS/MS using electrospray ionisation 
and atmospheric pressure chemical ionisation were found to be suitable for the 
detection of drugs of abuse like THC and its main metabolites [94, 112-120]. 
 
The following data show that our method has some distinct advantages, such as a 
high sensitivity (LLOQ of 0.2 ng/ml in plasma) and the detection of five cannabinoids 
from two matrices (human plasma and urine), compared to the already reported 
methods.  
 
The purpose of this paper is to describe a new, sensitive LC-MS/MS method for 
detection of THC and its metabolites, 11-OH-THC and THC-COOH, as well as CBD 
and CBN from human EDTA-plasma and urine. This method was used to 
characterise metabolic patterns of the compounds resulting from pharmacokinetic 
transformations that occur in humans following ingestion of hashish, marijuana and 
Cannabis sativa L. extracts.  
 
2. Experimental 
 
2.1. Chemicals 
 
THC and metabolite reference material was obtained from Lipomed (Arlesheim, 
Switzerland). All solvents (acetonitrile, isopropanol 20%, ortho-phosphoric acid 85%, 
ammonia solution 25%, diethylether, ethylacetate, acetic acid 100%, formic acid 
98%) and chemicals (ammonium formate, dipotassium hydrogen phosphate, 
potassium dihydrogen phosphate) in analytical grade were purchased from Merck 
(Darmstadt, Germany) and Aldrich (Buchs, Switzerland). Fetal bovine serum was 
obtained from Biochroma (Berlin, Germany) and urine quality controls from Biorad 
(Reinach, Switzerland). Silanised glass vials (type I plus) were purchased from 
Schott AG (Muellheim-Huegelheim, Germany) and 6 ml glass test tubes from Gilson 
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(Mettmenstetten, Switzerland). Solid-phase extraction was carried out on Certify II 
extraction cartridges from Varian (Zug, Switzerland). De-ionised water was generated 
with a Milli-Q water purification system from Millipore (Kloten, Switzerland). β-
glucuronidase was obtained from Roche Diagnostics GmbH (Mannheim, Germany). 
The buffer (pH 6.0, 0.1 M) was prepared with a KH2PO4 solution (13.61 g/950 ml 
water), adjusted to the desired pH by appropriate addition of KOH 1 M and filled up 
with water to one liter. The buffer (pH 9.1, 0.1 M) was prepared with a K2HPO4 
solution (8.71 g/480 ml water), adjusted to the desired pH by appropriate addition of 
ortho-phosphoric acid 85% and filled up with water to 500 ml. 
 
2.2. Specimens, standard solutions, calibration standards and 
quality controls 
 
Stock THC and metabolite standard solutions were made in acetonitrile/H2O (50/50, 
v/v). (The concentrations were THC, 11-OH-THC, CBD, CBN: 100 mg/l; THC-d3, 
THC-COOH-d3: 10 mg/l (v/v).) The standards were used to spike the matrix. 
Calibration standards for assay calibration and determination of the linear measuring 
range were prepared in bovine serum or human urine by spiking with the needed 
amount of the standard solutions to obtain the range of 0.2 - 100 ng/ml of THC and 
its metabolites. EDTA-plasma was taken from healthy male volunteers. After drawing, 
the blood was gently inverted, centrifuged (10 min at 2000 × g) and the supernatant 
filled in a silanised glass vial. The tubes were sealed and stored at -70 ° C.  
 
In order to determine for quality control purposes, the intra- and inter-assay precision 
and the accuracy, blood quality controls were prepared in blank bovine serum by 
spiking with THC (3.0, 10.0 and 25.0 ng/ml). The four commercially available urine 
quality controls contained 0, 37.5, 65.0 and 125.0 ng/ml THC-COOH.  
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2.3. Extraction procedure 
 
2.3.1. Human EDTA-plasma 
 
The solid-phase extraction procedure was carried out on Varian Bond Elut Certify II 
cartridges (off-line). Certify II is a mixed mode sorbent with an anion exchange 
sorbent and retains acidic and neutral drugs (THC and metabolites). The cartridges 
were conditioned initially with 1 ml acetonitrile and followed by 1 ml 0.1 M phosphate 
buffer (pH 9.1). 1 ml EDTA-plasma sample acidified with 20 µl ortho-phosphoric acid 
(85%) was loaded onto the cartridges. Cartridges were subsequently washed with 1 
ml 40% acetonitrile and dried under vacuum at 45 kPa for two minutes. The 
compound of interest was eluted with 1 ml acetonitrile:ammonia (NH4+) = 98:2 (v/v) 
into a 6 ml glass test tube and aliquots were evaporated to dryness at 37 ° C under 
nitrogen.  
 
2.3.2. Human urine 
 
First, a hydrolysation of THC-COOH-glucuronide to THC-COOH was done. To 2.5 ml 
urine 1 ml phosphate buffer (pH 6.0; 0.1 mmol/L) was added, mixed and 
supplemented with 50 µl β-glucuronidase. After vortexing, the sample was incubated 
at 50 ° C for 3h. The liquid-liquid extraction (LLE ) procedure for urine was carried out 
in glass tubes (off-line). One millilitre phosphate buffer (0.1 M, pH 6.0) and 1 ml of 
acetic acid 0.1 M were added to 2 ml of the de-glucuronised urine. After vortexing, 4 
ml organic phase (diethylether:ethylacetate 50% (v/v)) was added. After mechanical 
shaking (10 min) and centrifugation (10 min at 2000 × g), 3 ml of the organic phase 
were transferred to a 6 ml glass test tube and then evaporated to dryness at 37 ° C 
under nitrogen. 
 
The extracts were reconstituted in 60 µl of mobile phase (40% mobile phase A, 60% 
mobile phase B), 10 µl internal standard THC-d3 (EDTA-plasma), respectively, THC-
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COOH-d3 for urine analysis (10 mg/l in acetonitrile 50% (v/v)) was added, mixed and 
50 µl injected into the LC-MS/MS system (see section 2.4.1).  
The internal standard was added in order to overcome possible variations of the 
concentrations in the LC/detection system. Possible deviations of the extraction rates 
were overcome by treating the standards in both matrices (EDTA-plasma and urine) 
in the same way as samples and by calibrating each series of analysis.  
 
2.4. LC-MS/MS 
 
2.4.1. Chromatographic separation and mass spectral detection 
conditions 
 
The chromatographic system consisted of a Rheos 2000 Micro HPLC pump from 
Thermo Finnigan (Allschwil, Switzerland) and a Midas Symbiosis Autosampler from 
Spark (Emmen, Netherlands) equipped with a 100 µl loop. A four-channel degasser 
was integrated into the Rheos CPS LC system. The LC-MS/MS apparatus was a 
LCQ Advantage MAX from Thermo Finnigan (Allschwil, Switzerland) equipped with 
an APCI device operating in the positive detection mode. The chromatographic 
separation was performed on a Synergi MAX-RP 80A C12 column (length 2 mm × 75 
mm, i.d. 4 µm) from Brechbuehler (Zuerich, Switzerland). The mobile phase was 
delivered at a flow rate of 400 µl/min. Each chromatographic run was performed with 
a binary, linear A/B gradient (Solvent A was 10 mM ammonium formate, pH 3.0; 
Solvent B was 90% acetonitrile, 10% 10 mM ammonium formate, pH 3.0). The 
program was as follows: 0 min: 50% B; 1–12.0 min: 50–79% B; 12.01–12.50 min: 
79–95% B; 12.51–15.00 min: 95% B; 15.01–25.00 min: B linear from 95 to 50%. All 
solvents were degassed before usage.  
 
The following atmospheric pressure chemical ionisation inlet conditions were applied. 
The heated vaporiser was kept at 465 degrees Celsius. Both, the sheath gas and the 
auxiliary gas were nitrogen set at 60 and 15 relative units, respectively. The capillary 
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entrance to the ion trap was at an offset of 10 V in the positive mode and was 
maintained at 220 ° C. The corona current was 5 µA. For quantification, the selected 
ion monitoring mode was used. Table 1 lists the precursor and product ions and the 
relative collision energy for each analyte.  
Table 1: Precursor and product ions and the relative collision energy for each analyte  
Substance  
 
Mass APCI 
[M−H]+ (m/z) 
Product ions 
[M−H]+ (m/z) 
Collision energy (%) 
 
CBN 311.2 293.2 34 
CBD 315.1 259.2 34 
THC-COOH 345.2 327.1 30 
11-OH-THC 331.0 313.2 34 
THC 315.2 259.1 38 
 
 
2.5. LC-MS/MS assay validation 
 
2.5.1. Linear measuring range, quantification, lower limit of 
quantification (LLOQ), lower limit of detection (LLOD), quality 
controls, precision, accuracy and recovery 
 
2.5.1.1. Linear measuring range 
 
The linearity of the measuring range was assessed with standard curves ranging 
from 0.2 to 100 ng/ml (0.2; 0.3; 0.5; 1.0; 2.0; 3.0; 5.0; 10.0; 25.0; 50.0; 100.0 ng/ml) 
in bovine serum and human urine and analysed using the described LC-MS/MS 
method. Standard response curves were generated using a weighted (1/x) linear 
regression model.  
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2.5.1.2. Quantification 
 
The concentrations of the analytes were calculated by comparing the peak area (%) 
of an analyte with the corresponding area (%) on the standard curve. System 
variations were adjusted by comparing the areas (%) of the internal standards. The 
internal standards were THC-d3 for EDTA-plasma and THC-COOH-d3 for urine.  
 
2.5.1.3. The lower limit of quantification (LLOQ) and detection (LLOD) 
 
Bovine serum and human urine samples spiked with decreasing concentrations of 
the analytes were analysed in order to determine LLOQs and LLODs. Samples of 
each concentration were extracted and analysed five times. The LLOD was set at the 
lowest concentration where the signal of the compound was three standard 
deviations higher than the background noise. The LLOQs were determined by 
measuring five samples per concentration for all substances. The LLOQ was defined 
as the lowest concentration of THC and its metabolites which can still be determined 
with a precision <10% (CV).  
 
2.5.1.4. Precision 
 
Intra-assay precision was determined by replicate (n = 4) analysis of the QC samples 
in one run for both fluids.  
Inter-assay precision was determined by replicate analysis of the QC samples in 
several experiments performed on different days. Eight urine- and five EDTA-plasma 
samples were measured. A comparison with the nominal concentrations of the QC 
samples was used to assess the accuracy (bias) of the method. 
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2.5.1.5. Accuracy and recovery 
 
Accuracy was committed not to be >±20% of the nominal concentration.  
Recovery was estimated in both matrices by comparing the response of a blank 
human urine or a blank bovine serum spiked with 100 ng/ml analyte before the 
extraction step (n = 4) with the response obtained when the analyte was added to the 
corresponding matrix after the extraction procedure (n = 4). The deuterated internal 
standard was added in all samples after the extraction step under both conditions.  
 
2.5.2. Sample stability 
 
The stability of the cannabinoids during storage was monitored in human EDTA-
plasma (THC) and human urine samples spiked with the initial concentration of 100 
ng/ml for all measured substances. The concentrations in the samples were 
determined immediately after spiking (control samples, n = 3). Aliquots of the same 
samples were filled into silanised glass vials, closed with chlorbutyl gum stoppers 
and aluminium seals. The tubes were frozen at -70 ° C. The urine samples were 
thawed and measured (n = 3) after 62 and 133 days, the EDTA-plasma samples after 
21 and 41 days.  
 
For the evaluation of the freeze/thaw stability, the spiked sample (same sample 
material as above) was analysed before (control samples, n = 3) and after three 
freeze/thaw cycles (stability samples, n = 3). For each freeze/thaw cycle, the sample 
was frozen at -70 ° C for 24 h, thawed, extracted a nd measured.  
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2.5.3. Assessment of matrix effects 
 
To assess any possible suppression or enhancement of ionisation due to the sample 
matrix, four types of experiments were performed. In the first experiment blank 
samples from the test persons used as negative controls were analysed. The second 
test was to analyse blank bovine serum. The third trial included the evaluation of the 
matrix as described by Matuszewski et al. [94]. This assessment includes the 
recovery and process efficiency. For this test three sets of samples are necessary. 
Set A consists of aqueous standard solutions (100 ng/ml). For set B blank matrices 
are supplemented (after extraction) with the same amount of standards as used for 
set A. Set C consists of extracts of different blank matrices, supplemented with the 
same amount of standards but added before extraction. Recovery was calculated (for 
the calculation the resulting peak areas are needed) with the following formula: RE% 
= C/B × 100. Matrix effects were calculated with the formula: ME% = B/A × 100. 
Process efficiency was calculated with the formula: PE% = C/A × 100. The difference 
in analyte concentration not more than 50% was acceptable for all three tests.  
 
The last test provided a continuous post-column infusion [121] of an analyte in a 
chromatographic run of an extract or a blank matrix. This procedure is based on the 
post-column infusion of an analyte in a chromatographic run of an extract or a blank 
matrix. This signal is compared to the signal obtained with the post-column infusion 
of the same model analyte in a chromatographic run with eluent only. This procedure 
indicates also critical areas in the chromatogram.  
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3. Results and discussion 
 
An example of a typical chromatogram of 100 ng/ml of the analytes in bovine serum 
is shown in Figure 1. The retention times were 13.80 ± 0.08 min for THC, 7.38 ± 0.08 
min for 11-OH-THC, 7.75 ± 0.09 min for THC-COOH, 11.27 ± 0.08 min for CBD and 
13.00 ± 0.15 min for CBN. The total run time for each sample was 25 min. 
Acceptable retention times were considered to be within a time window of ± 0.5 min.  
 
 
Figure 1: LC-MS/MS chromatogram of 100 ng/ml of the analytes in bovine serum.  
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3.1. Linearity 
The linear measuring range was assessed with calibration curves ranging from 0.2 to 
100 ng/ml in bovine serum and human urine. Figure 2 shows an example of a 
standard response curve of each analyte in bovine serum generated using a 
weighted (1/x) linear regression model. The correlation coefficients (R2) in the 
diagrams were ≥0.994 with one acceptable exception of 0.979.  
 
 
Figure 2: Example of a standard response curve of each analyte in bovine serum. 
 
 
3.2. The lower limit of quantification (LLOQ) and detection (LLOD) 
 
The limit of quantification in EDTA-plasma was 0.2 ng/ml for CBN, THC, THC-COOH, 
CBD and 11-OH-THC, in urine 3 ng/ml for CBN, 1 ng/ml for CBD, THC and THC-
COOH and 2 ng/ml for 11-OH-THC.  
The limit of detection in EDTA-plasma for all substances was 0.1 ng/ml. The LLODs 
in urine were 0.5 ng/ml for THC, CBD and THC-COOH and 1 ng/ml for CBN and 11-
OH-THC.  
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3.3. Accuracy and intra- and inter-assay precision 
 
Results of the accuracy, intra- and inter-assay precision studies are presented in 
Table 2 and Table 3. The deviation of accuracy of the intra-assay study in EDTA-
plasma (THC) and urine (THC-COOH) did generally not exceed 18% (accepted 
20%).  
 
Table 2: Results of the intra-assay precision  
Intra-assay precision 
 
 
Urine (THC-COOH) EDTA-plasma (THC) 
Number of measurements (n) 4 4 4 4 4 4 
Mean (ng/ml) 28.5 65.7 132.5 3.0 8.2 24.9 
Nominal concentration (ng/ml) 37.5 65.0 125.0 3.0 10.0 25.0 
S.D. (ng/ml) 3.0 0.9 1.7 0.2 0.4 1.9 
CV (%) 10.5 1.4 1.3 8.8 5.2 7.9 
Accuracy (%) 24.0 1.0 6.0 0.0 18.0 0.4 
S.D.: Standard deviation; CV: coefficient of variation. 
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Table 3: Results of the inter-assay precision  
Inter-assay precision (ng/ml)  
Urine (THC-COOH) EDTA-plasma (THC) 
Number of measurements (n) 8 8 8 5 5 5 
Mean (ng/ml) 27.8 64.7 132.6 2.9 8.8 27.0 
Nominal concentration (ng/ml) 37.5 65.0 125.0 3.0 10.0 25.0 
S.D. (ng/ml) 4.3 4.2 3.9 0.6 1.1 1.6 
CV (%) 15.5 6.5 1.9 11.8 12.8 7.9 
Accuracy (%) 26.0 0.4 5.6 3.3 12.0 8.0 
S.D.: Standard deviation; CV: coefficient of variation. 
 
The deviation in the lowest concentrated urine control sample was 24% (intra) and 
26% (inter) which exceeds the acceptable value (20%). This fact was ignored 
because of possible method differences in the choice of the nominal concentrations 
and a good precision (with coefficients of variation of 10.5% (intra-assay) and 15.5% 
(inter-assay)). In both matrices (EDTA-plasma and urine) the intra- and inter-assay 
precision displayed by the CV was much better than 20% (defined acceptable CV by 
the authors). CVs were in the range 1.3 - 10.5 (intra-assay) and 1.9 - 15.5 (inter-
assay).  
 
3.4. Stability 
 
In urine, the substance stability tests at a temperature of -70 ° C in silanised glass 
vials showed that the concentrations of each cannabinoid with the exception of THC 
did not decrease more than 20% after 5 months (mean of three measurements). THC 
concentration showed a decrease of 26%. In EDTA-plasma, the THC concentration 
decreased steadily during the observation period with a decrease of 30% after 21 
days and 43% after 41 days.  
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3.5. Assessment of matrix effects 
 
Blood and urine samples from the test persons were taken immediately before the 
administration of the cannabis drug. The samples were used as negative controls 
and to compare the baseline chromatograms with those after the drug application. No 
peaks with measurable areas were found in the chromatograms (data not shown).  
 
3.6. Blank bovine serum used as negative controls 
 
Blank bovine serum was measured to compare the chromatograms with the spiked 
bovine serum samples used for the standard curves. No peaks with measurable 
areas were found in the blank bovine serum chromatograms (data not shown). Table 
4 shows the recovery, matrix effects and process efficiency of the analytes. No 
statement about value acceptability was described by Matuszewski et al 
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Table 4: Recovery, matrix effect and process efficiency  
Recovery (%) Matrix effects (%) Process efficiency (%)  
Bovine serum Urine Bovine serum Urine Bovine serum Urine 
THC 77.5 78.7 97.6 87.9 70.7 70.3 
11-OH-THC 77.6 63.4 117.6 154.2 91.5 142.6 
CBD 71.4 70.0 84.2 93.1 60.0 69.5 
CBN 47.7 78.1 73.4 85.1 34.7 68.7 
THC-COOH 50.0 61.4 172.9 283.8 87.5 173.9 
Parameters were determined according to Matuszewski et al. [94]. 
 
3.7. Recovery 
All studies show enough recovery (%) for each substance in both matrices (range 
47.7 - 78.7) in relation to the sensitivity results (LLOD/LLOQ).  
 
3.8. Matrix effects 
 
This study showed the low influence on the qualitative and quantitative 
determinations, which was confirmed by the test after Matuszewski (Table 4). The 
range of this study was 73.4 - 283.8% and shows a common effect for several 
substances in different matrices on the extraction rate over 100% yield compared to 
aqueous standards.  
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3.9. Process efficiency 
 
The sensitivity for the determination of the substances is high enough for the analysis 
in the samples of the provided trial. This is due to overall good process efficiency. 
One exception was CBN because of a low recovery (47.7%), bad process efficiency 
(34.7%) and a relatively high LLOD.  
 
3.10. Post-column infusion after Bonfiglio et al. [121] 
 
The post-column infusion (100 µl/min) of the cannabinoids in a chromatographic run 
of eluent only, indicated no critical areas in the chromatograms compared with those 
of blank human urine and bovine serum. No critical area around the retention time of 
THC or the other analytes was detected (data not shown). No change in the 
ionisation process (enhancement, suppression of the ionisation) of an analyte due to 
a co-eluting compound was found. 
 
3.11. An example of determination after administration of 
cannabinoids to human subjects 
 
The described method was applied to determine the pharmacokinetics of THC and its 
metabolites after administration of either 20 mg synthetic THC (Marinol™) or an 
extract from Cannabis sativa L. (capsule containing 20 mg of cannabinoids) to the 
same healthy male volunteer. Figure 3 and Figure 4 show that the metabolites are 
detectable for at least 24 h. Except after the intake of THC, no CBD was detectable 
in the EDTA-plasma. 
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Figure 3: Plasma concentration time curve of THC and its major metabolites as well as CBD and CBN 
after the intake of 20 mg synthetic THC (Marinol™) in one healthy male subject.  
 
 
 
Figure 4: Plasma concentration time curve of THC and its major metabolites as well as CBD and CBN 
after the intake of a Cannabis sativa L. extract (containing 20 mg of cannabinoids) in one healthy male 
subject.  
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The range of the measured cannabinoid concentrations is within 0 - 16.0 ng/ml. The 
consumption of THC (Marinol™) shows higher concentrations compared to those 
after the administration of the herbal extract.  
 
3.12. Comparison with other methods 
 
The analysis of plasma and urine samples for cannabinoids by GC/MS is daily 
routine in forensic toxicology laboratories. Normally, the investigations are limited to 
THC, 11-OH-THC and THC-COOH and detection limits of 1 ng/ml are sufficient. 
However, in the present study, CBD and CBN had to be included and a detection 
limit below 0.5 ng/ml was necessary in order to follow up the concentrations for a 
sufficiently long time after drug administration.  
Only 2 - 2.5 ml plasma per sample were available. Therefore, the method, particularly 
the extraction, had to be adapted to these requirements before application to the 
study.  
 
The described LC-MS/MS method allows the simultaneous analysis of five 
cannabinoids from urine or plasma in the same run over 25 min. There are several 
other methods published in the literature so far. Most reported methods detect only 
one or two metabolites from one matrix. Another important issue of cannabinoid 
analytics, especially for forensic purposes, is a high sensitivity. The described 
method has a LLOQ of 0.2 ng/ml and is more sensitive than previously described 
analytical methods used in pharmacokinetic trials. Most of those reported methods 
show LLOQs >5 ng/ml.  
 
Only one GC/MS method reported likewise the simultaneous analysis in plasma of 
THC, 11-OH-THC, CBN, CBD and THC-COOH. This method had a slightly lower 
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sensitivity with a LLOQ of 0.5 - 3.9 ng/ml and had a run time of 13 min [122]. 
However, this method is more elaborate than ours. 
 
Compared to other reported GC/MS methods [108-111] for estimation of THC or its 
metabolites, definite advantage of our LC-MS/MS method is a gain of time. There is 
no need to do an elaborate sample preparation and to use various derivatisation 
techniques for non-volatile and thermolabile compounds like in GC/MS.  
 
4. Conclusions 
 
We developed and validated a sensitive and selective method for the determination 
of THC, its major metabolites as well as CBD and CBN in human EDTA-plasma and 
urine, using high-performance liquid chromatographic separation with tandem-mass 
spectrometry detection which showed a satisfactory overall analytical performance 
well suited for applications in medical science. With a LLOQ of 0.2 ng/ml (EDTA-
plasma), pharmacokinetic profiles of the drugs and their concentrations could be 
determined for up to 24 h after a single oral administration of a Cannabis sativa L. 
extract capsule of 20 mg THCtot (Fig. 3 and Fig. 4). The stability tests showed a 
constant decrease of THC in urine and of all parameters in EDTA-plasma. This 
decrease does not exceed 10% if the samples are analysed within a short time 
period. This method is very efficient because it permits the measurement of low 
concentrations and the simultaneous quantification of five analytes.  
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3.2. Sensitivity and specificity of urinary cannabinoid detection 
with two immunoassays after controlled oral administration of 
cannabinoids to humans 
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Abstract 
 
Background: For forensic and clinical toxicological purposes, cannabis 
consumption is screened using easy to handle immunoassays. The sensitivity and 
specificity of these immunoassays have not yet been established in samples from 
volunteers receiving oral synthetic THC or cannabis extracts, using tandem mass 
spectrometry (LC-MS/MS) as the reference method. 
 
Methods: Urine samples were collected in an open, randomised, single-center, 
three-periods cross-over study including 18 healthy male volunteers, given either 
20 mg synthetic THC (MarinolTM) as a control substance or 5 different types of 
Cannabis sativa L. extracts. The study was performed according to the guidelines 
set forth in the Declaration of Helsinki at the University Hospital Basel, Switzerland. 
Only male volunteers were accepted, they had to be cannabis-naϊve with a good 
ability to understand German. The subjects were informed about the aims, 
methods, anticipated benefits, potential hazards and discomfort the study may 
entail, as well as the subjects right to abstain from participating in the study and to 
withdraw their consent at any time. They gave their written informed consent that 
has been approved by the local State Ethics Committee of the two cantons Basel 
(EKBB) and were paid for participating. There were a lot of exclusion criteria all of 
which will be published in an upcoming paper.  
 
All urine samples were collected and frozen at -70 ° C until analysis. Urinary 11-
nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) excretion was 
evaluated by two immunoassays (CEDIA, FPIA) using the National Institute on 
Drug Abuse (NIDA) and a Substance Abuse and Mental Health Service (SAMHSA) 
set general immunoassay cut-off value of 50 ng/ml as well as an approved LC-
MS/MS method [123] with a cut-off value of 15 ng/ml. The sensitivity, specificity and 
cut-off values were evaluated by a ROC-curve analysis. All urine samples were 
measured with and without enzymatic hydrolysis to analyse the reactivity in the two 
immunoassays and the concentrations of both THC metabolites (THC-COOH-
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glucuronide, THC-COOH) with LC-MS/MS. At the same time the direct 
hydrolysation rate by the MS method in the ion source was determined. 
 
Results: The ROC curve analysis indicated that the FPIA test discriminated better 
than the CEDIA test. The results show that the NIDA set general immunoassay cut-
off of 50 ng/ml is possibly not applicable for analysis in samples from persons 
consuming the Cannabis sativa L. extracts orally instead of smoking. It has to be 
discussed whether a general cut-off value for the two immunoassays is applicable 
or not. LC-MS/MS is an excellent confirmation method for the continuation of 
immunoassay results, allowing the detection of many cannabinoids. The enzymatic 
hydrolysis method showed a nearly 100% transformation of THC-COOH-
glucuronide to THC-COOH. 
 
Conclusions: The use of cannabinoid-based therapeutics and continued abuse of 
oral cannabis require scientific data for accurate interpretation of cannabinoid tests 
and for establishing a reliable administrative drug-testing policy. Preliminary 
positive immunoassay results have to be confirmed by a second, more specific 
analysis method such as GC-MS or LC-MS. For correct quantitative results of the 
analytes, it is important to include the glucuronides in the analysis. From our data it 
is not possible to set a general method-independent cut-off value for 
immunoassays when cannabinoids are consumed orally as extracts. 
 
1. Introduction 
 
Laboratory analyses of cannabinoids or other drugs have forensic, criminal and 
clinical applications. Urine, blood, saliva and hair are the common matrices for the 
detection of drugs. The collection of urine is easy. The drugs and their metabolites 
found in urine can be detected for a longer time frame after drug ingestion 
compared to blood or saliva [55]. A hydrolysation of the urine before the analysis, to 
convert drug conjugates (glucuronides) to their free metabolites, is advantageous 
for several analytical techniques. The rate of false positive or false negative results 
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should be minimised in an analytical method. To achieve this objective, two steps 
are necessary. To identify positive specimens a screening step has to be 
performed. The principle of an immunoassay test is the use of antibodies binding to 
the drug, but its selectivity is limited by the specificity of the antibodies used in the 
immunoassay. False positive results can be caused if substances chemically 
similar to the drug or its metabolites interfere in the test. A sample concentration 
below the accepted threshold, or a dilution or adulteration of the sample to obscure 
the presence of a drug, can lead to false negative results. Unfortunately, in a 
screening test often cross-reacting substances and different cross-reactivities with 
metabolites often have to be considered [56]. Therefore, preliminary positive 
immunoassay results have to be confirmed by a second, more specific analysis 
method such as mass spectrometry (MS) [55, 57].  
 
Urine contains creatinine, a metabolic waste product removed from muscle tissue. 
It is filtered from the blood by the kidney and excreted without reabsorption in the 
urine. For measuring drugs excreted into the urine, the drug-to-creatinine ratio is 
often used to normalise different measurements if they have to be compared [124]. 
 
The principal psychoactive component of Cannabis sativa L. is ∆9-
tetrahydrocannabinol (THC). After intake in humans, 11-hydroxy-∆9-
tetrahydrocannabinol (11-OH-THC) is the major psychoactive THC metabolite 
formed. Due to its pharmacokinetic properties (high concentration) [125-127], the 
non-psychotropic 11-nor-∆9-tetrahydrocannabinol-carboxylic acid (THC-COOH) is 
usually accepted as the metabolite for drug testing with immunoassays, 
disregarding the long half-life of about 30 h. However, this long half-life renders this 
metabolite questionable for testing in shortly after drug intake. THC-COOH and its 
glucuronide are the main metabolites in urine. 
 
To assess the sensitivity and specificity of two routinely used semi-quantitative 
immunoassays (CEDIA: Microgenics, FPIA: Abbott Laboratories) for urinary THC-
COOH determination, human urine samples from a study were analysed by these 
two immunoassays, using a cut-off value of 50 ng/ml and by tandem mass- 
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spectrometric analysis (LC-MS/MS) with a cut-off value of 15 ng/ml [123]. The 18 
healthy male volunteers received either 20 mg synthetic THC (MarinolTM) as a 
control substance or 5 different types of Cannabis sativa L. extracts containing 20 
mg THCtot. 
 
The objectives of the present study were to compare the results of these two 
immunoassays with our quantitative LC-MS/MS method that was used as the gold 
standard. Specific objectives were a) to discuss the SAMHSA set THC carboxylic 
acid cut-off for immunoassays in the special samples of this trial, b) to determine 
the cross-reactivity of the sum of THC-COOH-glucuronide and THC carboxylic acid 
with both methods, before and after hydrolysis, c) to assess the influence of other 
metabolites on the immunoassay results, and d) to assess, whether the 
measurements of THC-COOH only, without considering other cannabis 
metabolites, as it is the standard in all urine drug of abuse screening procedures, 
will be valuable too after oral intake of Cannabis Sativa L. extracts with lower THC 
concentrations and possibly different metabolism. 
 
 
2. Materials and Methods 
 
2.1. Chemicals  
 
THC and metabolite reference material were obtained from Lipomed (Arlesheim, 
Switzerland). All solvents (acetonitrile, isopropanol 20%, ammonia solution 25%, 
diethylether, ethylacetate, acetic acid 100%, formic acid 98%) and chemicals 
(ammonium formate, potassium dihydrogen phosphate) were analytical grade and 
were purchased from Merck (Darmstadt, Germany) and Aldrich (Buchs, 
Switzerland). Urine quality control samples were purchased from Biorad (Reinach, 
Switzerland) for LC-MS/MS. The reagents, quality controls and calibrators for the 
immunoassays were obtained from Microgenics (Fremont, CA, USA) for CEDIA 
 Publications   
 76 
immunoassay and from Abbott (Abbott Park, IL, USA) for AxSYM THC-COOH 
immunoassay. Silanised glass vials (type I plus) were purchased from Schott 
(Muellheim-Huegelheim, Germany) and 6 ml glass test tubes from Gilson 
(Mettmenstetten, Switzerland). De-ionised water was generated with a Milli-Q water 
purification system from Millipore (Kloten, Switzerland). β-glucuronidase was 
obtained from Roche Diagnostics GmbH (Mannheim, Germany). The buffer (pH 
6.0, 0.1 mol/L) was prepared from a KH2PO4 solution (13.61 g in 950 ml water), 
adjusted to the desired pH by appropriate addition of KOH 1 mol/L and adjusted to 
1 L with water.  
 
2.2. Specimens, standard solutions, calibration standards and 
quality controls  
 
Stock THC and metabolite standard solutions were prepared in acetonitrile/H2O 
(50/50, v/v). (The concentrations were 100 mg/l for THC, 11-OH-THC, cannabidiol 
(CBD), cannabinol (CBN), THC-COOH and 10 mg/l (v/v) for THC-d3, THC-COOH-
d3). The standards were used to spike a blank urine matrix (Biorad liquicheck urine 
toxicology control, level 0). Calibration standards for assay calibration and 
determination of the linear measuring range were prepared in human urine by 
spiking with the necessary amount of the standard solutions to obtain a linear 
calibration curve in the range of 0.5 -100 ng/ml of THC and its metabolites. 
 
To determine the performance of the method, the intra- and inter-assay precision 
and the accuracy were assessed for LC-MS/MS [123]. Four commercially available 
urine quality controls for THC-COOH were used (Biorad liquicheck urine toxicology 
controls, level 0, 1, 2, 3). For the FPIA, THC assay quality controls from Abbott 
(Abbott Park, IL, USA) were used (low and high). The CEDIA THC assay uses the 
following quality control levels: THC 25 (low, high), THC 50 (low, high) and THC 
100 (low, high) from Thermo Fisher (Allschwil, Switzerland). For the analysis of 
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creatinine, quality controls from Microgenics (MAS Urichem TRAK, levels 1 and 2) 
were obtained. 
 
2.3. Extraction procedure  
 
First, a hydrolysis of THC-COOH-glucuronide to THC-COOH was performed. To 
2.5 ml urine, 1 ml phosphate buffer (pH 6.0; 0.1 mmol/L) was added, mixed and 
supplemented with 50 µl β-glucuronidase. After vortexing, the sample was 
incubated at 50 ° C for 3h. The liquid–liquid extra ction (LLE) procedure for urine 
was carried out in glass tubes (off-line). One ml phosphate buffer (0.1 M, pH 6.0) 
and 1 ml of acetic acid 0.1 mol/L were added to 2 ml of the de-glucuronised urine. 
After vortexing, 4 ml organic phase (diethylether/ethylacetate 50% (v/v)) was 
added. After mechanical shaking (10 min) and centrifugation (10 min at 2000 × g), 
3 ml of the organic phase was transferred to a 6 ml glass test tube and then 
evaporated to dryness at 37 ° C under nitrogen. The  extracts were reconstituted in 
60 µl of mobile phase (40% mobile phase A, 60% mobile phase B), 10 µl internal 
standard THC-COOH-d3 (10 mg/l in acetonitrile 50% (v/v)) was added, mixed and 
50 µl injected into the LC-MS/MS system. 
 
The internal standard was added in order to overcome possible variations of the 
concentrations in the extraction step and in the LC/detection system. Possible 
deviations of the extraction rates were overcome by treating the standards in the 
same way as samples and by calibrating each series of analyses. For strict 
scientific reasons the use of a deuterated THC-COOH-glucuronide internal 
standard would have been preferred. At the moment, there is no commercial THC 
carbonic acid glucuronide available which is stable enough and we did not have the 
possibility to produce ourselves. Because of the direct hydrolysis in the LC-MS 
system we did not investigate the analysis of another glucuronidated internal 
standard (see 3.1.). 
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All urine samples were measured with and without enzymatic hydrolysis to compare 
the total concentration of THC-COOH with the concentration produced by a 
spontaneous hydrolysis in the ion source of the LC-MS/MS detector. 
 
2.4. Human urine 
Human urine was collected from healthy male volunteers at the following time 
points: 0, 4, 12, 24, 48, 72 h. The samples were sealed and stored at -70 ° C in 
silanised glass vials until measurement. As reported previously [123], the limit of 
quantification in urine with the LC-MS/MS method was 3 ng/ml for CBN, 1 ng/ml for 
CBD, THC and THC-COOH and 2 ng/ml for 11-OH-THC. The limit of detection in 
human urine was 0.5 ng/ml for THC, CBD and THC-COOH and 1 ng/ml for CBN 
and 11-OH-THC. 
 
2.5. Immunoassays 
 
The CEDIA assay for THC uses recombinant DNA technology to produce an 
enzyme immunoassay system. The antibodies are monoclonal. The SAMHSA set 
general cut-off is 50 ng/ml. The accuracy by recovery is guaranteed up to a 
concentration of 100 ng/ml. The CEDIA Microgenics immunoassay for THC-COOH 
was from Thermo Fisher (Passau, Germany). Enzymatic creatinine was obtained 
from Wako (Neuss, Germany). Both assays were performed on a Roche Hitachi 
917 system (Indianapolis, IN, USA).  
 
The FPIA THC assay uses a sheep polyclonal antibody. The SAMHSA set general 
cut-off of this assay is 50 ng/ml. The accuracy by recovery is guaranteed up to a 
concentration of 135 ng/ml. The FPIA assay was from Abbott Laboratories (Abbott 
Park, IL, USA) and performed on an AxSYM analyser (Abbott Park, IL, USA). For 
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both immunoassays only a few cross-reactions with THC metabolites are known 
and presented in the package insert. 
 
2.6. LC-MS/MS  
 
The LC-MS/MS analysis was performed with a validated high-performance liquid 
chromatographic method with tandem-mass spectrometric detection, as previously 
reported [123]. In brief: the chromatographic system consisted of a Rheos 2000 
Micro HPLC pump (Thermo Fisher, Allschwil, Switzerland) and a Midas Symbiosis 
Autosampler from Spark (Emmen, Netherlands) equipped with a 100 µl loop. A 
four-channel degasser was integrated into the Rheos CPS LC system. The LC-
MS/MS apparatus was a LCQ Advantage MAX from Thermo Fisher (Basel, 
Switzerland) equipped with an APCI device operating in the positive ionisation 
mode. The chromatographic separation was performed on a Synergi MAX-RP 80A 
C12 column (length 2 mm × 75 mm, i.d. 4 µm) from Brechbuehler (Zuerich, 
Switzerland). The mobile phase was delivered at a flow rate of 400 µl/min. Each 
chromatographic run was performed with a binary, linear A/B gradient (Solvent A 
was 10 mmol/L ammonium formate, pH 3.0. Solvent B was 90% acetonitrile, 10% 
10 mmol/L ammonium formate, pH 3.0). The program was as follows: 0 min: 50% 
B; 1 - 12.0 min: 50 - 79% B; 12.01 - 12.50 min: 79 - 95% B; 12.51 - 15.00 min: 95% 
B; 15.01 - 25.00 min: B linear from 95 to 50%. All solvents were degassed before 
use.  
 
The following APCI inlet conditions were applied: The heated vaporiser was kept at 
465 ° C. Both, the sheath gas and the auxiliary gas  were nitrogen set at 60 and 15 
relative units, respectively. The capillary entrance to the ion trap was at an offset of 
10 V in the positive mode and was maintained at 220 ° C. The corona current was 5 
µA. For quantification, the selected ion monitoring mode was used.  
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2.7. Sensitivity, specificity and cut-off value 
 
For the determination of the sensitivity and specificity of the two immunoassay 
results, LC-MS/MS determinations of cannabinoids in urine after hydrolysis were 
performed using the chromatographic method as the gold standard. Sensitivity and 
specificity of the immunoassays without hydrolysis were calculated as:  
 
negativesfalseofnumberpositivestrueofnumber
positivestrueofnumberysensitivit
+
=   
positivesfalseofnumbernegativestrueofnumber
negativestrueofnumberyspecificit
+
=  
 
The cut-off value was determined as the limit for decisions (yes/no) as to whether a 
result should be interpreted as positive or negative. The recommendations of 
SAMSHA for cut-off values for cannabinoid analysis are 50 ng/ml (FPIA, CEDIA) 
and 15 ng/ml (LC-MS/MS). These cut-offs are set after studies indicating a very low 
probability giving false positive results after passive inhalation of cannabinoids. All 
these cut-off values are based on experimental work and not by pharmacokinetic 
studies of drug excretion. 
 
2.8. ROC curve analysis 
 
In signal detection theory, a receiver operating characteristic (ROC-curve), is a 
graphical plot of the sensitivity vs. (1 - specificity) for a binary classifier system as 
its discrimination threshold is varied. The ROC curve can also be represented 
equivalently by plotting the fraction of true positives vs. the fraction of false 
positives [128, 129]. 
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Sensitivity and specificity of the immunoassays were assessed by a ROC analysis. 
For this analysis each sample was classified by its THC-COOH LC-MS/MS result 
after hydrolysis as the gold standard. This classification was compared to the 
classifications of results obtained by two immunoassays (CEDIA, FPIA) using the 
SAMHSA cut-offs. If the concentration was above the cut-off value of 15 ng/ml (LC-
MS/MS), the sample was classified to be positive for THC-COOH.  
 
 
3. Results and discussion 
 
3.1. Urine samples measured with and without enzymatic 
hydrolysis  
 
Urine samples from the clinical trial after the intake of oral cannabinoids were 
measured using the LC-MS/MS, FPIA and CEDIA methods. All samples were 
stored at -70 ° C before analysis, thawed and measu red with and without 
hydrolysis. For the LC-MS/MS method the hydrolysis procedure showed a total 
transformation of the THC-COOH-glucuronide in the detection system confirmed by 
the nearly 100% agreement of the total concentrations after hydrolysis and the sum 
of free THC-COOH in the un-hydrolysed samples. Figure 1 shows an example of 
an extracted urine sample measured before and after enzymatic hydrolysis by LC-
MS/MS. The THC-COOH-glucuronide in contrary to free THC-COOH is nearly not 
retained in the HPLC separation column and is presumably totally hydrolysed in the 
vaporisation step at the entrance of the APCI nozzle because of the high 
temperature of about 500 ° C. Otherwise there would  not be any signal with the 
mass spectrum of THC-COOH (main and daughter ions, Figure 1). The two 
immunoassays showed a nearly 100% cross-reactivity with the glucuronide 
showing no difference between the results before and after hydrolysis. 
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THC-COOH-glucuronide:      1021.16 pmol/ml 
THC-COOH:                        105.16 pmol/ml 
Total:                       1126.32 pmol/ml 
THC-COOH-glucuronide:       0.00 pmol/ml 
THC-COOH:                     1101.30 pmol/ml 
Total:                                1101.30 pmol/ml 
 
Figure 1: One urine sample measured with and without enzymatic hydrolysis with LC-MS/MS. 
 
 
3.2. Sensitivity, specificity and cut-off values 
 
In Table 1, the results in agreement, as well as the false positive and false negative 
sample numbers are listed. Both immunoassays showed false negative and false 
positive results. The CEDIA test showed more discrepancies than the FPIA test. 
Nearly no quantitative difference in the number of false positive/negative values 
was determined between the pure and de-glucuronised samples in all tests.  
 
 
 
 
 
 
 
enzymatic  
hydrolysis 
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Table 1: Sensitivity and specificity data for 50 ng/ml (CEDIA/FPIA) and 15 ng/ml (LC-MS/MS) cut-offs. 
LC-MS/MS 
HYDROLYSED URINE 
(THC-COOH TOTAL) 
LC-MS/MS NATIVE URINE  
(THC-COOH+THC-COOH-
GLUCURONIDE) 
 
negative positive negative positive 
neg 105 34 105 34 
CEDIA  pos 22 164 27 160 
neg 104 57 114 56 CEDIA  
hydrolysed  pos 17 146 21 141 
neg 100 18 102 16 
FPIA  pos 16 171 22 165 
neg 102 19 102 18 FPIA  
hydrolysed pos 14 179 19 172 
 
CEDIA: Cloned enzyme donor immunoassay 
FPIA: Fluorescence polarisation immunoassay 
Pos: positive (higher than 15ng/ml (LC-MS/MS)/50 ng/ml (Immunoassay)) 
Neg: negative (lower than 15ng/ml (LC-MS/MS)/50 ng/ml (Immunoassay)) 
 
 
3.3. ROC curve analysis 
 
The following ROC curve shows the discrimination power of the two 
immunoassays. The ROC analysis in Figure 2 indicates that the FPIA test 
discriminates better than the CEDIA test. Tests with lower performance tend 
towards the 45° diagonal (CEDIA) whereas those with  good performance curves 
move upward and leftward (FPIA). With a probability of 94.7% in the FPIA test, any 
selected accidental value from the positive group is higher than any selected 
accidental value from the negative group. CEDIA had a probability of 88.6%. These 
results show that the SAMHSA set general immunoassay cut-off of 50 ng/ml is 
possibly not applicable for analysis of samples from persons consuming the 
Cannabis sativa L. extracts orally. At this cut-off the FPIA assay shows a sensitivity 
of 90.6% and a specificity of 86.2%, whilst the CEDIA assay shows a sensitivity of 
82.8% and a specificity of 82.7%. Optimum cut-off values are then evident as being 
the best combined value for highest sensitivity when traded against specificity, i.e. 
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the test cut-off related to the top-left point on the graph. In this population any 
change for a higher sensitivity will decrease the specificity in both assays. This 
shows that it is impossible to fix a new general cut-off independent of the method. 
An explanation for these differences between the immunoassays in our study 
population could be an insufficient stability of the reagents in the CEDIA test. The 
laboratory of the University Hospital in Basel recognised a decrease of signals in 
the assays when kits were used shortly before their expiration date.  
 
The high rate of false positive results could be explained by cross-reactivity of the 
immunoassays with metabolites not approved by the manufacturers of the kits and 
possible interactions with other substances. The tests are only developed to 
measure THC-COOH concentrations in the urine samples produced after smoking 
cannabinoids and not after oral consumption. But there are some other compounds 
with a similar chemical structure which cross-react with the test. In Table 2, cross-
reactivity results of the parent compounds and metabolites are given for the CEDIA 
and FPIA THC assay. 
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Figure 2: ROC curve of two immunoassays vs. LC-MS/MS with cut-offs 50 ng/ml  
(FPIA, CEDIA) and 15 ng/ml LC-MS/MS.  
 
Table 2: Cross-reactivity of cannabinoids in the CEDIA and FPIA THC assay  
(Reproduced after the package insert of both tests) 
compound tested (ng/ml) % cross reactivity test 
11-nor-∆9-THC-COOH 50 100 
11-nor-∆8-THC-COOH 40 125 
∆9-THC 500 10.4 
11-OH-∆9-THC 125 43 
8β-OH-∆9-THC 1000 2.8 
8β, 11-di-OH-∆9-THC 5000 8.4 
1--∆9-THC-glucuronide 62 78 
Cannabinol 1000 2.9 
Cannabidiol 1000 < 0.1 
CEDIA 
11-nor-∆8-THC-9-carboxylic acid 25 
11-OH-∆9-THC 25 
Cannabinol 80 
 FPIA 
Other metabolites - - both 
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4. Conclusions 
 
Our results show that LC-MS/MS is an excellent confirmation method for 
immunoassays allowing the detection of many cannabinoids.  
 
Our results further suggest that it is important to include the THC-COOH- 
glucuronide in the urine analysis to get correct quantitative results of the analytes 
when measured by LC-MS/MS. In the described LC-MS/MS method, the 
glucuronide is automatically detected together with THC-COOH. The glucuronide is 
directly hydrolysed at the high tempered (500 ° C) vaporisation step in the APCI 
nozzle in the detector. 
 
We used the described enzymatic hydrolysis method with β-glucuronidase to confirm 
the total transformation of the THC-COOH-glucuronide to THC-COOH in the detector 
system and for trials with the immunoassays. 
 
The cut-offs for the sum of urinary excretion products cross-reacting in the 
immunoassays from Microgenics CEDIA and Abbotts FPIA for the classification of 
oral cannabinoid intake do not seem to be optimal after intake of oral cannabinoids. 
Lower cut-off values for the immunoassays might increase the sensitivity but 
decrease the specificity, however, this has to be confirmed by further studies. From 
our results we can not recommend a cut-off for immunoassays for sample testing 
after the intake of cannabis extracts. 
 
Both immunoassays are routinely used and established methods. A possible 
explanation for the higher than expected rate of false positive and false negative 
results for the measurement of THC-COOH by both assays could be that they usually 
detect the analyte in urine samples of patients inhaling the smoke of cannabis and 
the lower dose of THC in the extracts. The results described in this paper may result 
from the analysis of urine samples after oral intake of cannabinoids. An interesting 
aspect is that the immunoassay results (negatives and positives) correspond nearly 
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100% with the LC-MS/MS results of analysis in the same samples after cannabis 
smoking. It is possible that additional substances in the oral capsule formulations 
disturb the immunoassay tests. 
 
The urine samples were derived from subjects receiving cannabis extracts orally 
instead of smoking THC containing cigarettes. We suppose that the concentrations of 
metabolites differ strongly depending on the route of application. The amount and 
appearance of different metabolites may disturb the immunoassay methods. 
 
Another interesting aspect is that many concentrations in the MS 
positive/immunoassay negative population correspond with each other (47% in the 
MS positive/FPIA negative group and 70% in the MS positive/CEDIA negative 
group). Both tests often showed the same concentrations which actually seem to be 
optimal. The concentrations evaluated with the SAMHSA defined cut-off values, 
however, lead to a high rate of discrepancy of false negative/positive results. 
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3.3. Relative Bioavailabilities of Different Oral Formulations of Extracts of 
Cannabis sativa. 
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Abstract 
 
This review describes an open, randomised, single-center, three-periods cross-over 
phase I study including 18 healthy, male volunteers, with different, standardised 
Cannabis sativa L. extracts and MarinolTM as control substance. The best Cannabis 
sativa L. extract capsule formulation was evaluated for a possible future 
implementation as a new, concomitant medicament in cancer, HIV and AIDS therapy 
instead of a synthetic medication like MarinolTM. The study was performed in two 
parts in parallel. In the first part, the heating-effect on the relative content of 
cannabinoids was investigated. In the second study part, the effect of Cannabis 
sativa L. extract capsule formulations, containing different concentrations of TPGS, 
on the bioavailabilities of different active cannabinoids was assessed. The plasma 
concentrations of the cannabinoids were assessed with an approved LC-MS/MS 
method. The study endpoints were a) to assess the relative bioavailability of ∆9-
tetrahydrocannabinol and its metabolites defined as area under the plasma 
concentration/time curve from time T = 0 h extrapolated to infinity (AUC(0-∞)), b) to 
assess the relative tolerability and safety of six different oral formulations of 20 mg 
∆9-tetrahydrocannabinoltot (∆9-tetrahydrocannabinol and ∆9-tetrahydrocannabinol 
acid A), c) to assess the effect of six different oral formulations of 20 mg ∆9-
tetrahydrocannabinoltot on psychomotor function defined as simulator assisted 
evaluation of driving ability, d) to assess repetitive heart rate, blood pressure and a 
visual analogue scale (VAS) for sedation. The pharmacokinetic of the cannabinoids 
was highly variable between the subjects. Due to this variability, no statistically 
significant differences between the AUC of the different forms could be detected, 
neither in part I nor in part II of the study. There was a significantly different pattern of 
cannabinoids between the treatments. The extracts have a slightly lower 
bioavailability of total cannabinoids than MarinolTM. However, the pharmacological 
effects seem to be comparable. TPGS addition leads to a qualitatively different 
pattern of cannabinoid metabolites. Addition of TPGS increases the bioavailability of 
cannabinoids up to about 135% compared to extracts without TPGS (=100%) without 
deteriorating tolerability. It can, therefore, be concluded that the administration of 
Cannabis sativa L. extracts is safe. The pharmacodynamic results are reported in a 
second, separate publications. 
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1. Introduction 
 
Worldwide, the use of natural cannabis products for medical purposes is practically 
not allowed. In contrast, drugs containing synthetic cannabinoids like dronabinol 
(MarinolTM), a synthetic THC are often exempt from these restrictions. The United 
States Food and Drug Administration (FDA) approved MarinolTM to treat nausea and 
vomiting associated with cancer chemotherapy in patients who have failed to 
respond adequately to conventional treatments. Furthermore, the FDA approved 
MarinolTM to treat appetite loss associated with weight loss in people with acquired 
immunodeficiency syndrome (AIDS). It was shown in recent studies that THC or 
cannabis preparations have a promising potential as a releasing factor, in moving 
disorders and as a pain reducer in patients suffering from multiple sclerosis.  
 
In naturally grown Cannabis sativa L., up to 95% of the occurring total cannabinoids 
(THCtot) are in the form of ∆9-tetrahydrocannabinolic acid A (THCA-A) [25]. By 
heating to 200 - 210 ° C for 5 minutes, THCA-A is q uantitatively decarboxylised to 
phenolic THC [7]. It is usually assumed that conversion to THC during smoking is 
complete, however, recently THCA-A was detected in blood and urine in samples 
collected from police controls of drivers suspected for driving under the influence of 
drugs [24]. The % of THCA-A / THC was 8-18% in these samples. Although THCA-A 
is described as pharmacologically inactive and devoid of psychotropic effects [7], 
reports of popular medicinal use of unheated cannabis or cannabis preparations 
show pharmacological effects often accompanied with a lower rate of adverse effects 
(anecdotal reports). It also possesses some anti-inflammatory and analgesic effects 
[8]. Recently, it was shown that unheated cannabis extract was able to inhibit tumor 
necrosis factor alpha in macrophage culture and peripheral marcrophages after LPS 
stimulation [9].  
 
Although cannabidiol (CBD), a cannabinoid occurring in the natural grown cannabis 
plant, is devoid of psychotropic effects (e.g. euphoria, effects on cognition and 
behavior) it may have some beneficial effects (such as sedating, anticonvulsant, anti-
inflammatory, and neuroprotective effects [29, 130-133]). 
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Plant extracts may be superior to administration of synthetic THC for treating medical 
diseases because of a well-balanced combination of active substances which can be 
found in the natural cannabis plant. Therefore, in the present study, the 
pharmacokinetics of five different Cannabis sativa L. extracts are compared with 
those after the oral administration of synthetic THC. Natural plant extracts of 
Cannabis sativa L. contain a large amount of THCA-A, which is transformed to THC 
by heating. Because of the potentially beneficial effect of THCA-A, four unheated 
cannabis extracts and only one heated extract were used in the clinical trial. 
 
There are two problems of oral administrations of synthetic THC or Cannabis sativa 
L. extracts: the low oral bioavailability and large intra- and intersubject variability in 
the pharmacokinetics and pharmacodynamics. The low enteral absorption of 
cannabinoids may be a result of gastrointestinal efflux pumps in the intestinal 
mucosa (such as P-glycoprotein). Substrates of P-glycoprotein are very efficiently 
transported back from the enterocytes into the gut lumen immediately after 
absorption. These substrates usually show a limited and highly variable oral 
absorption. It was recently shown that THC and other cannabinoids are interacting 
with P-glycoprotein and with BCRP (another intestinal efflux pump) [134-137]. 
Therefore, it was a secondary objective of the present study to investigate, whether 
inhibition of P-glycoprotein function could enhance enteral absorption of 
cannabinoids and possibly decrease the pharmacokinetic variability. For this 
purpose, D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS, Eastman, USA) 
was used. TPGS has been used as a solubilising agent and absorption enhancer in 
different oral drug formulations (e.g. cyclosporine) [12, 138-141]. However, up to 
now, the mechanism of the absorption enhancing effect is not yet clear. Besides 
improving solubility of lipophilic compounds, it is also a potent inhibitor of P-
glycoprotein [12, 138, 141, 142]. 
 
Four different unheated Cannabis sativa L. extracts have been studied: Without and 
with 0.5, 5.0 and 7.5% TPGS to assess dose-dependent effects of TPGS. 
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2. Materials and methods  
 
2.1. Subjects and study design 
 
An open, randomised, single center, three-periods cross-over clinical phase I study 
with different Cannabis sativa L. extracts and MarinolTM, a synthetic THC medication 
was performed to evaluate the best Cannabis sativa L. extract capsule formulation 
for a possible future implementation as a new, concomitant medication in cancer, HIV 
and AIDS treatment. 
 
The study was performed according to the guidelines set forth in the Declaration of 
Helsinki at the University Hospital in Basel, Switzerland. The clinical trial was 
performed in two parts in parallel. Both parts were performed in nine healthy 
(interview to the past medical history; measurements of blood pressure, heart rate, 
temperature, height, weight and ECG; blood and urine baseline assessments), 
cannabis-naïve, male volunteers with a good ability to understand German, each. 
The subjects were informed about the aims, methods, anticipated benefits, potential 
hazards and the discomfort the study may entail, as well as the subject’s right to 
abstain from participating in the study and to withdraw their consent at any time. 
They gave their written informed consent that has been approved by the local State 
Ethics Committee of the two cantons Basel (EKBB) and were paid for participating. 
Exclusion criteria were history or indication of drug abuse (including alcohol and 
drugs; a urinary screening for cannabinoids and opiates was assessed before each 
session), known or suspected hypersensibility to cannabinoids, presence of 
significant cardiovascular, hepatic, endocrine or renal diseases, smoking, subjects 
unable or unwilling to comply fully with the protocol and participating in any other 
clinical study. Drop outs were replaced. A post-study examination of the subjects was 
assessed at the end of the clinical trial. Drug administration was given to the subjects 
at 8 a.m. after a fasting period of at least twelve hours. Four hours after start of the 
administration, a standardised liquid meal was ingested (Ensure 500ml containing a 
caloric content of 2090 kJ) and after seven hours a standardised snack (roll with a 
slice of ham or cheese, an apple and 0.3 l orange juice) was given. The subjects 
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were allowed to drink ad libitum mineral water. The study protocol, the CRFs, the 
Investigator's Brochure, and the informed consent form were submitted to the local 
State Ethics Committee of both cantons of Basel (EKBB) for review and approval. An 
exceptional permit for scientific use of THC, cannabinoids and MarinolTM was 
obtained by the Federal Office for Public Health. The study was notified to the Swiss 
health agency (Swissmedic). This study was carried out in accordance with the 
recommendations of the Declaration of Helsinki adopted by the 18th WMA General 
Assembly Helsinki, Finland, June 1964 and finally amended by the 52nd WMA 
General Assembly, Edinburgh, Scotland, October 2000.  
 
Each subject received either 20 mg THC (dronabinol, MarinolTM soft gelatine 
capsules; Unimed Pharmaceuticals, Inc., Marietta, GA, USA, through DiaMo 
Narcotics Ltd., Thun, Switzerland), or one of five different encapsuled Cannabis 
sativa L. extract formulations (chapter 2.2.). Plant extracts were manufactured by 
Frutarom (Wädenswil, Switzerland). Galenical formulation was done by the Institute 
for Hospital Pharmacy, University Hospital Basel according to GMP regulations. All 
capsule formulations were standardised containing 20 mg THCtot. The blinding of the 
test medications was performed by two investigators by enclosing the test medication 
capsules in another, dark-coloured glass flask named with the letters A-F depending 
on the medication content. 
 
In the first study part, the effect of heating on the relative content of cannabinoids 
was investigated. Data were compared to the commercial formulation MarinolTM. In 
the second study part, the effect of different formulations with TPGS on the 
bioavailabilities of different active cannabinoids was investigated. The study 
endpoints were a) to assess the relative bioavailabilities of THC and its metabolites 
assessed as area under the plasma concentration/time curve from time T = 0 h 
extrapolated to infinity (AUC(0-∞)), b) to assess the relative tolerability and safety of 
six different oral formulations of 20 mg THCtot (THC and THCA-A), c) to assess the 
effect of six different oral formulations of 20 mg THCtot on psychomotor function 
assessed as simulator assisted evaluation of driving ability, d) to assess repetitive 
heart rate, blood pressure and a visual analogue scale (VAS) for sedation. 
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The wash-out phases between the consecutive treatments were at least two weeks 
depending on the outcome of the urinary screening (fluorescence polarisation 
immunoassay (FPIA); cloned enzyme donor immunoassay (CEDIA)) for THC-COOH. 
If a test was positive for THC-COOH (SAMHSA set general immunoassay cut-off of 
50 ng/ml) after two weeks, it was repeated seven days later and then in weekly 
intervals until the test was negative for the THC-COOH. 
 
Blood (5 - 10 ml) was collected in all sessions through a cubital vein catheter of the 
forearm at baseline, 0.5, 1, 2, 4, 8, 12, 24 h and additionally at 48 and 72 h in the 
second study phase post drug intake. 
 
The blood samples were gently inverted, centrifuged (10 min at 2000 × g) and the 
supernatant (EDTA-plasma) filled in silanised glass vials. The vials were sealed and 
instantly deep-frozen at -70 ° C until analysis. ED TA-plasma concentrations of THC 
and its metabolites 11-OH-THC and THC-COOH as well as cannabidiol (CBD) and 
cannabinol (CBN) were measured with an approved LC-MS/MS method [123] after 
an off-line solid-phase extraction. 
 
In this paper version only the pharmacokinetic calculations of the study are 
described, evaluated and discussed. The pharmacodynamic results are reported in 
another, separate publication. 
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2.2. Study Medication 
 
All subjects received each of the treatments in a double-blind manner according to a 
randomised cross-over design. The different treatments are described in Table 1. The 
study dose was chosen, since it is used as a standard dose in clinical studies with 
THC and cannabinoids. 
 
Table 1: Study medication 
Part A 
Medication A 20 mg ∆9-THC (MarinolTM, reference medication). 
Medication B Cannabis extract from herba cannabis (heated), corresponding to 
20 mg ∆9-THCtot and 20-30 mg CBDtot. 
Medication C Cannabis extract from herba cannabis (unheated), corresponding 
to 20 mg ∆9-THCtot and 20-30 mg CBDtot. 
Part B 
Medication D Cannabis extract from unheated herba cannabis (containing 20 
mg ∆9-THCtot and 20-30 mg CBDtot) + 0.5 % TPGS. 
Medication E Cannabis extract from unheated herba cannabis (containing 20 
mg ∆9-THCtot and 20-30 mg CBDtot) + 5 % TPGS. 
Medication F Cannabis extract from unheated herba cannabis (containing 20 
mg ∆9-THCtot and 20-30 mg CBDtot) + 7.5 % TPGS. 
 
 
2.3. Summary of Demographic Characteristics of Subjects and 
Disposition of subjects 
 
Nineteen subjects entered the study and received at least one administration of a 
study drug (ten for Part I and nine for Part II). One subject (no. 1) discontinued his 
participation due to mild to moderate adverse effects on his second administration 
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day, where he had received Marinol (Form A). He experienced mild paresthesia, 
warm feeling, conjunctional injection, vertigo, visual disturbances, abdominal 
discomfort, dry mouth, tremor and paleness as well as moderate short-lasting 
anxiety. Since, the symptoms were in the vast majority of mild severity, this subject 
was replaced. The other 18 subjects completed the study.  
 
Demographic characteristics of the subjects are listed in Table 2. 
 
Table 2: Summary of demographic characteristics of subjects 
  
Age 
(years) 
Weight 
(kg) 
Height 
(cm) 
BMI 
(kg/cm2) 
N  19 17 19 17 
Mean  26.8 75.5 177.8 23.9 
Median  25 76 178 24.1 
Std. Deviation  4.76 7.77 4.31 2.59 
Std. Error  1.09 1.88 0.96 0.63 
95% confidence  
interval for mean 
Lower bound 
21 64 167 18.7 
 Upper bound 40 95 188 29.3 
Minimum  26.8 64 177.8  
Maximum  25 95 178  
 
 
2.4. Chemicals  
 
THC and metabolite reference material was obtained from Lipomed (Arlesheim, 
Switzerland). All solvents (acetonitrile, isopropanol 20%, ortho-phosphoric acid 
85%, ammonia solution 25%, formic acid 98%) and chemicals (ammonium formate, 
dipotassium hydrogen phosphate) in analytical grade were purchased from Merck 
(Darmstadt, Germany) and Aldrich (Buchs, Switzerland). Fetal bovine serum was 
obtained from Biochroma (Berlin, Germany). Silanised glass vials (type I plus) were 
purchased from Schott (Muellheim-Huegelheim, Germany) and 6 ml glass test 
tubes from Gilson (Mettmenstetten, Switzerland). Solid-phase extraction was 
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carried out on Certify II extraction cartridges from Varian (Zug, Switzerland). De-
ionised water was generated with a Milli-Q water purification system from Millipore 
(Kloten, Switzerland). The buffer (pH 9.1, 0.1 M) was prepared with a K2HPO4 
solution (8.71 g/480 ml water), adjusted to the desired pH by appropriate addition of 
ortho-phosphoric acid 85% and filled up with water to 500 ml. 
 
2.5. Specimens, standard solutions, calibration standards and 
quality controls 
 
Stock THC and metabolite standard solutions were made in acetonitrile/H2O (50/50, 
v/v). (The concentrations were THC, 11-OH-THC, CBD, CBN: 100 mg/l; THC-d3, 
THC-COOH-d3: 10 mg/l (v/v).) The standards were used to spike the matrix. 
Calibration standards for assay calibration and determination of the linear measuring 
range were prepared in bovine serum by spiking with the needed amount of the 
standard solutions to obtain the range of 0.2 - 100 ng/ml of THC and its metabolites. 
EDTA-plasma was taken from healthy male volunteers. In order to determine for 
quality control purposes, the intra- and inter-assay precision and the accuracy, blood 
quality controls were prepared in blank bovine serum by spiking with THC (3.0, 10.0 
and 25.0 ng/ml). 
 
2.6. Extraction procedure of human EDTA-plasma 
 
The solid-phase extraction procedure was carried out on Varian Bond Elut Certify II 
cartridges (off-line). Certify II is a mixed mode sorbent with an anion exchange 
sorbent and retains acidic and neutral drugs (THC and metabolites). The cartridges 
were conditioned initially with 1 ml acetonitrile and followed by 1 ml 0.1 M phosphate 
buffer (pH 9.1). 1 ml EDTA-plasma sample acidified with 20 µl ortho-phosphoric acid 
(85%) was loaded onto the cartridges. Cartridges were subsequently washed with 1 
ml 40% acetonitrile and dried under vacuum at 45 kPa for 2 min. The compound of 
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interest was eluted with 1 ml acetonitrile:ammonia (NH4+) = 98:2 (v/v) into a 6 ml 
glass test tube and aliquots were evaporated to dryness at 37 ° C under nitrogen.  
 
The extracts were reconstituted in 60 µl of mobile phase (40% mobile phase A, 60% 
mobile phase B), 10 µl internal standard THC-d3 (10 mg/l in acetonitrile 50% (v/v)) 
was added, mixed and 50 µl of the mixture injected into the LC-MS/MS system.  
 
The internal standard was added in order to overcome possible variations of the 
concentrations in the LC/detection system. Possible deviations of the extraction rates 
were overcome by treating the standard in EDTA-plasma in the same way as 
samples and by calibration each series of analysis.  
 
2.7. LC-MS/MS 
 
The LC-MS/MS analysis was performed with a validated high-performance liquid 
chromatographic separation method with tandem-mass spectrometry, as previously 
reported [123]. In brief: the chromatographic system consisted of a Rheos 2000 
Micro HPLC pump (Thermo Fisher, Allschwil, Switzerland) and a Midas Symbiosis 
Autosampler from Spark (Emmen, Netherlands) equipped with a 100 µl loop. A 
four-channel degasser was integrated into the Rheos CPS LC system. The LC-
MS/MS apparatus was a LCQ Advantage MAX from Thermo Fisher (Basel, 
Switzerland) equipped with an APCI device operating in the positive detection 
mode. The chromatographic separation was performed on a Synergi MAX-RP 80A 
C12 column (length 2 mm × 75 mm, i.d. 4 µm) from Brechbuehler (Zuerich, 
Switzerland). The mobile phase was delivered at a flow rate of 400 µl/min. Each 
chromatographic run was performed with a binary, linear A/B gradient (Solvent A 
was 10 mM ammonium formate, pH 3.0. Solvent B was 90% acetonitrile, 10% 10 
mM ammonium formate, pH 3.0). The program was as follows: 0 min: 50% B; 1 - 
12.0 min: 50 - 79% B; 12.01 - 12.50 min: 79 - 95% B; 12.51 - 15.00 min: 95% B; 
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15.01 - 25.00 min: B linear from 95 to 50%. All solvents were degassed before 
usage.  
 
The following APCI inlet conditions were applied: The heated vaporiser was kept at 
465 ° C. Both, the sheath gas and the auxiliary gas  were nitrogen set at 60 and 15 
relative units, respectively. The capillary entrance to the ion trap was at an offset of 
10 V in the positive mode and was maintained at 220 ° C. The corona current was 5 
µA. For quantification, the selected ion monitoring mode was used.  
 
2.8. Study analytes and their Lower Limits of Quantification (LLOQ) 
and Detection (LLOD) 
 
Plasma concentrations of THC and its metabolites 11-OH-THC and THC-COOH as 
well as cannabidiol and cannabinol were measured with this approved LC-MS/MS 
method. The LLOQ in EDTA-plasma was 0.2 ng/ml, the LLOD 0.1 ng/ml for all 
substances. 
 
2.9. Pharmacokinetic Parameters 
 
The following pharmacokinetic parameters have been assessed: The maximum 
plasma concentration (Cmax) and the time of its occurrence (Tmax) have been 
determined by inspection of raw data. The area under the plasma concentration / 
time curve (AUC) has been determined by linear trapezoidal rule. If appropriate, 
plasma profiles were to be evaluated by model dependent analysis using non-linear 
regression (WinNonlin version 5.0; copyright  Pharsight Corporation 2006). 
Otherwise, non-parametric analysis using WinNonlin had to be applied. The following 
parameters have been determined: Area under the plasma concentration / time curve 
over the first 24 hours after drug administration, the maximum plasma concentration 
(Cmax) and the time of its occurrence (Tmax). The concentrations of the analytes were 
calculated by comparing the peak area (%) of an analyte with the corresponding area 
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(%) on the standard curve. System variations were adjusted by comparing the area 
(%) of the internal standard THC-d3. 
 
2.10. Statistical and analysis plan 
 
Descriptive analysis of all parameters has been performed. For all medications, 
analysis of variance and subsequent Tukey multicomparison test (normally 
distributed data) or Friedman test with subsequent multiple Wilcoxon signed ranks 
test with Bonferoni’s correction was used for data not normally distributed, as 
appropriate. 
 
All statistical analyses have been performed with the SPSS for Windows software 
(version 14.0). All comparisons have been performed as two-tailed analyses. The 
level of significance was p= 0.05. 
 
3. Results and Discussion 
 
3.1. Pharmacokinetic evaluation 
 
Mean pharmacokinetic data are displayed in Figure 1 (1a-1f) and Figure 2 (2a-2f). 
The summary of the pharmacokinetic data is given in Table 3 and 5. Data are given 
in molar concentrations to allow an estimation of absorption independent of different 
molecular weights of THC metabolites.  
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3.1.1. Plasma levels Part I (heated/unheated extracts, MarinolTM) 
 
Although there were some slight differences in the pharmacokinetic parameters AUC, 
Cmax and Tmax, values of THC showed no statistically significant differences. This was 
due to the high inter-subject variability. 
AUC and Cmax values of 11-OH-THC showed no statistically significant differences. 
However, after administration of the unheated extract significantly (P = 0.042) shorter 
Tmax values were observed (1.00 ± 0.14 (1.0) hours) than after administration of 
MarinolTM (1.67 ± 0.17 (2.0) hours).  
 
AUC and Cmax values of THC-COOH showed no statistically significant differences. 
However, after administration of the heated and unheated extract significantly (P = 
0.05) longer Tmax values were observed (2.89 ± 0.35 (1.0) hours and 2.11 ± 0.26 (2.0) 
hours, respectively) than after administration of MarinolTM (1.78 ± 0.32 (22.0) hours).  
 
As expected, no CBD plasma concentrations could be detected after administration 
of the synthetic THC (MarinolTM). Although after administration of the unheated 
extract the AUC of CBD was about 2-fold higher (7.67 ± 2.06 (4.63) pmol×h/ml) than 
after administration of the heated extract (3.68 ± 1.34 (2.53) pmol×h/ml), this 
difference was not statistically significant. Cmax values were significantly different 
between the treatments (P = 0.002): after administration of the unheated extract, 
Cmax amounted to 3.95 ± 0.92 (3.06) pmol/ml) and after administration of the heated 
extract to 0.94 ± 0.22 (0.87) pmol/ml. Although Tmax values were longer for the 
unheated than heated extract, this difference was not statistically significant. 
 
For CBN, no significant differences could be detected for AUC, Cmax and Tmax 
between the treatments. 
 
Although mean values indicated large difference in AUC values of overall absorption 
(as expressed as the AUC (0-24h) of the sum of THC, 11-OH-THC, THC-COOH and 
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CBN), median values were comparable between the treatments: Form A= 149.13 ± 
44.24 (99.98) pmol×h/ml, Form B= 181.15 ± 90.54 (90.57) pmol×h/ml and Form C= 
62.53 ± 14.04 (60.36) pmol×h/ml. Hence, no statistical differences could be detected. 
Likewise, no statistically significant differences could be detected for Cmax values, 
although, values were about 2-fold higher after administration of MarinolTM than after 
administration of both extracts. Tmax values were significantly higher after 
administration of the heated extract (2.67 ± 0.33 (2.0) h) than after administration of 
MarinolTM (1.44 ± 0.18 (1.0) h; P = 0.005) or the unheated extract (1.22 ± 0.21 (1.0) 
h; P = 0.001).  
 
A summary of the pharmacokinetic data (study part I) is presented in Table 3. Mean ± 
SEM plasma concentration curves of the cannabinoids are presented in Figure 1. 
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Table 3: Summary of pharmacokinetic data: Study part I (Means ± SEM (Median))  
 
 
 
Study part I Marinol 20 mg Heated extract Unheated extract 
(1) ∆9THC    
AUC(0-24) 
(pmol×h/ml) 8.43 ± 4.23 (4.58) 3.48 ± 0.84 (2.84) 9.75 ± 2.95 (6.59) 
Cmax (pmol/ml) 3.26 ± 1.74 (1.53) 1.33 ± 0.42 (0.8) 3.24 ± 0.83 (2.26) 
Tmax (h) 1.06 ± 0.19 (1.0) 0.78 ± 0.09 (1.0) 1.17 ± 0.22 (1.0) 
    
(2) 11-OH-THC 
   
AUC(0-24) 
(pmol×h/ml) 9.51 ± 2.07 (6.86) 10.61 ± 3.83 (7.24) 7.52 ± 2.15 (7.27) 
Cmax (pmol/ml) 2.99 ± 0.65 (2.53) 2.22 ± 0.69 (1.51) 1.72 ± 0.41 (1.5) 
Tmax (h) 1.67 ± 0.17 (2.0) 1.44 ± 0.23 (2.0) 1.00 ± 0.14 (1.0) 
    
(3) THC-COOH 
   
AUC(0-24) 
(pmol×h/ml) 121.94 ± 39.91 (84.32) 157.80 ± 85.16 (70.68) 39.03 ± 10.44 (45.14) 
Cmax (pmol/ml) 20.71 ± 5.47 (22.11) 16.88 ± 7.34 (10.04) 5.62 ± 1.06 (6.62) 
Tmax (h) 1.78 ± 0.32 (2.0) 2.89 ± 0.35 (2.0) 2.11 ± 0.26 (2.0) 
    
(4) CBN 
   
AUC(0-24) 
(pmol×h/ml) 10.66 ± 4.70 (7.14) 9.25 ± 1.91 (8.41) 6.23 ± 2.23 (3.77) 
Cmax (pmol/ml) 2.05 ± 0.78 (1.19) 1.94 ± 0.40 (1.82) 1.74 ± 0.31 (1.88) 
Tmax (h) 1.06 ± 0.19 (1.0) 0.94 ± 0.15 (1.0) 1.00 ± 0.14 (1.0) 
    
(5) CBD 
   
AUC(0-24) 
(pmol×h/ml) 0.00 ± 0.00 (0.0) 3.68 ± 1.34 (2.53) 7.67 ± 2.06 (4.63) 
Cmax (pmol/ml) 0.00 ± 0.00 (0.0) 0.94 ± 0.22 (0.87) 3.95 ± 0.92 (3.06) 
Tmax (h) NA 0.83 ± 0.17 (0.5) 1.17 ± 0.39 (1.0) 
    
6) Sum [(1) – (4)] 
   
AUC(0-24) 
(pmol×h/ml) 149.13 ± 44.24 (99.98) 181.15 ± 90.54 (90.57) 62.53 ± 14.04 (60.36) 
Cmax (pmol/ml) 26.90 ± 6.53 (27.47) 19.73 ± 8.03 (12.29) 10.47 ± 1.86 (12.29) 
Tmax (h) 1.44 ± 0.18 (1.0) 2.67 ± 0.33 (2.0) 1.22 ± 0.21 (1.0) 
Bioavailability (%) 100 345.7 ± 180.5 (83.3) 57.4 ± 12.6 (60.4) 
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Figure 1: 1a-1e: Mean ± SEM plasma concentrations of THC, 11-OH-THC, THC-COOH, CBD, CBN 
(pmol/ml) in study part I. 1f: Mean ± SEM of total concentrations THC and metabolites (11-OH-THC, 
THC-COOH, CBN) (pmol/ml) in study part I 
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After administration of cannabis extracts, a different metabolic pattern was detected 
(Table 4): 
 
Table 4: Percentage of total AUC (0-24h) of different metabolites in study part I 
Form THC 11-OH-THC THC-COOH CBD CBN 
Form A 
MarinolTM 
5.45 ± 1.04 
(5.13) 
9.70 ± 2.03 
(8.79) 
76.44 ± 3.50 
(80.83) 
0.0 ± 0.0 
(0.0) 
8.41 ± 2.66 
(6.98) 
Form B 
Heated extract 
3.39 ± 1.05 
(2.46) 
7.53 ± 1.54 
(6.14) 
77.02 ± 4.08 
(77.16) 
3.02 ± 1.09 
(1.50) 
9.04 ± 2.43 
(7.68) 
Form C 
Unheated extract 
15.82 ± 3.32 
(11.37) 
10.42 ± 1.69 
(12.30) 
48.55 ± 6.82 
(55.34) 
14.85 ± 4.40 
(12.56) 
10.35 ± 3.00 
(5.67) 
 A: P = 0.005 
B: P = 0.001 
 
A: P = 0.002 
B: P = 0.001 
A: P = 0.001 
B: P = 0.01 
 
 
 
After administration of Form C (unheated extract), the highest proportion of THC AUC 
of all cannabinoids were observed (15.82 ± 3.32 (11.37) %). This proportion was 
significantly higher than after administration of Form A (MarinolTM; 5.45 ± 1.04 (5.13) 
%, P = 0.005) and after administration of Form B (heated extract; 3.39 ± 1.05 (2.46); 
P = 0.001). The proportion of 11-OH-THC and CBN was virtually unchanged between 
the different treatments. The largest differences were seen for the proportion of THC-
COOH: the unheated extract showed the lowest proportion (48.55 ± 6.82 (55.34) %), 
which was significantly (P = 0.001) lower than that after administration of the heated 
extract (77.02 ± 4.08 (77.16) %) and also lower (P = 0.002) than after administration 
of MarinolTM (76.44 ± 3.50 (80.83) %). 
 
After administration of the synthetic MarinolTM, no plasma concentrations of CBD 
could be detected. This was expected, since THC is not converted to CBD in vivo 
and is found only in cannabis plants. Heating of extracts decreased the proportion of 
CBD significantly (P = 0.01) from 14.85 ± 4.40 (12.56) % for the unheated to 3.02 ± 
1.09 (1.50) % for the heated extract.  
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3.1.2. Plasma levels Part II (0.5, 5, 7.5 % TPGS) 
 
The highest values of THC AUC (0-24h) were observed after administration of Form 
E (unheated extract containing 5% TPGS). These values amounted to 9.73 ± 1.53 
(8.93) pmol×h/ml and were statistically significant greater (P = 0.04) than after 
administration of Form F (unheated extract containing 7.5% TPGS): 4.96 ± 1.02 
(4.61) pmol×h/ml. After administration of Form D (unheated extract containing 0.5% 
TPGS), AUC was 6.02 ± 1.28 (4.06) pmol×h/ml, which was not significantly different 
from the AUC value after administration of Form E. After administration of Form E, 
Cmax values were significant higher (2.83 ± 0.39 (2.87) pmol/ml) than after 
administration of Form D (1.66 ± 0.33 (1.26) pmol/ml; P = 0.039) and Form F (1.45 ± 
0.21 (1.58) pmol/ml; P = 0.014). Maximum plasma concentrations were most rapidly 
observed after administration of Form E (0.89 ± 0.16 (1.0) h) than after administration 
or Form E (0.94 ± 0.15 (1.0) h) and finally Form D (1.33 ± 0.39 (1.0) h). However, 
these differences were not statistically significant different. 
 
The values of 11-OH-THC AUC (0-24h), Cmax and Tmax were not statistically 
significant different between the treatments. AUC values amounted to 6.77 ± 2.28 
(4.07), 6.30 ± 1.56 (4.87) and 6.14 ± 1.44 (6.68) pmol×h/ml after administrations of 
Forms D, E and F, respectively. Cmax values amounted to 1.37 ± 0.26 (1.61), 2.13 ± 
0.69 (1.22) and 1.69 ± 0.40 (1.58) pmol/ml after administrations of Forms D, E and F, 
respectively. Tmax values amounted to 2.00 ± 0.43 (2.0), 1.50 ± 0.20 (2.0) and 1.50 ± 
0.20 (2.0) h after administrations of Forms D, E and F, respectively.  
 
The values of THC-COOH AUC (0-24h), Cmax and Tmax were likewise not statistically 
significant different between the treatments. However, as indicated by the median 
values there was a trend of higher AUC and Cmax values and shorter Tmax values after 
administration of Form E. AUC values amounted to 61.90 ± 18.99 (35.22), 57.60 ± 
11.66 (49.63) and 53.94 ± 10.03 (45.5) pmol×h/ml after administrations of Forms D, E 
and F, respectively. Cmax values amounted to 8.21 ± 2.15 (6.05), 10.32 ± 2.40 (8.06) 
and 8.26 ± 1.35 (7.84) pmol/ml after administrations of Forms D, E and F, 
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respectively. Tmax values amounted to 2.89 ± 0.68 (2.0), 1.56 ± 0.18 (2.0) and 2.11 ± 
0.26 (2.0) h after administrations of Forms D, E and F, respectively.  
 
The values of CBN AUC (0-24h), Cmax and Tmax were likewise not statistically 
significant different between the treatments. AUC values amounted to 10.17 ± 1.31 
(10.8), 11.21 ± 2.28 (9.23) and 11.55 ± 2.03 (11.32) pmol×h/ml after administration of 
Form D, E and F, respectively. Cmax values amounted to 1.59 ± 0.19 (1.64), 1.95 ± 
0.28 (2.05) and 1.66 ± 0.29 (1.52) pmol/ml after administrations of Forms D, E and F, 
respectively. Tmax values amounted to 2.11 ± 0.39 (2.0), 2.33 ± 0.44 (2.0) and 2.11 ± 
0.39 (2.0) h after administrations of Forms D, E and F, respectively.  
 
The highest values of CBD AUC (0-24h) and Cmax were observed after administration 
of Form D (6.11 ± 0.95 (7.87) pmol×h/ml and 3.68 ± 1.03 (2.49) pmol/ml, 
respectively). These values gradually decreased with increasing TPGS content: over 
4.85 ± 0.46 (5.25) pmol×h/ml (AUC) and 3.20 ± 0.36 (2.92) pmol/ml (Cmax) after 
administration of Form E to 3.34 ± 0.68 (2.65) pmol×h/ml (AUC) and 2.30 ± 0.36 
(1.75) pmol/ml (Cmax) after administration of Form F. For AUC the difference between 
AUC values after administration of Form D and E was statistically significant (P = 
0.033). Tmax were likewise not statistically significant different between the 
treatments. AUC values amounted to 6.11 ± 0.95 (7.87), 4.85 ± 0.46 (5.25) and 3.34 
± 0.68 (2.65) pmol×h/ml after administrations of Forms D, E and F, respectively. Cmax 
values amounted to 3.68 ± 1.03 (2.49), 3.20 ± 0.36 (2.92) and 2.30 ± 0.36 (1.75) 
pmol/ml after administrations of Forms D, E and F, respectively. Tmax values 
amounted to 1.17 ± 0.36 (1.0), 0.78 ± 0.09 (1.0) and 0.72 ± 0.09 (0.5) h after 
administration of Form D, E and F, respectively. Tmax values showed a trend to 
decrease with high TPGS content; however, this was not statistically significant. 
 
No significant differences between the treatments were observed for AUC (0-24h), 
Cmax and Tmax of total cannabinoids (sum of THC, 11-OH-THC, THC-COOH and 
CBN). AUC values amounted to 84.36 ± 20.84 (58.29), 84.84 ± 12.13 (79.12) and 
76.59 ± 10.34 (58.29) pmol×h/ml after administration of Form D, E and F, 
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respectively. Cmax values amounted to 10.86 ± 2.46 (9.18), 15.54 ± 2.60 (14.32) and 
11.60 ± 1.49 (9.18) pmol/ml after administration of Form D, E and F, respectively. 
Tmax values amounted to 2.89 ± 0.68 (2.0), 1.56 ± 0.18 (2.0) and 2.11 ± 0.26 (2.0) h 
after administrations of Forms D, E and F, respectively.  
 
When mean values of the administrations of different unheated extracts were 
compared for total cannabinoids (estimate of total oral bioavailability), TPGS addition 
resulted in an increased relative bioavailability (versus administration of unheated 
extract without TPGS (=100%) in study part I) of 134.91%, 135.88% and 122.49% 
after administration of Forms D, E and F, respectively. 
 
A summary of the pharmacokinetic data (study part II) is presented in Table 5. Mean 
± SEM plasma concentration curves of the cannabinoids are presented in Figure 2. 
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Table 5: Summary of pharmacokinetic data: Part II (Means ± SEM (Median)  
Study part II Form D 
Unheated extract, 0.5 % TPGS 
Form E 
Unheated extract, 5.0 % TPGS 
Form F 
Unheated extract, 7.5 % TPGS 
(1) ∆9-THC    
AUC(0-24) (pmol×h/ml) 6.02 ± 1.28 (4.06) 
 
9.73 ± 1.53 (8.93) 
vs. Form F: P = 0.04 
4.96 ± 1.02 (4.61) 
 
Cmax (pmol/ml) 1.66 ± 0.33 (1.26) 
 
 
2.83 ± 0.39 (2.87) 
vs. Form D: P = 0.039 
vs. From F: P = 0.014 
1.45 ± 0.21 (1.58) 
 
 
Tmax (h) 1.33 ± 0.39 (1.0) 0.89 ± 0.16 (1.0) 0.94 ± 0.15 (1.0) 
    
(2) 11-OH-THC 
   
AUC(0-24) (pmol×h/ml) 6.77 ± 2.28 (4.07) 6.30 ± 1.56 (4.87) 6.14 ± 1.44 (6.68) 
Cmax (pmol/ml) 1.37 ± 0.26 (1.61) 2.13 ± 0.69 (1.22) 1.69 ± 0.40 (1.58) 
Tmax (h) 2.00 ± 0.43 (2.0) 1.50 ± 0.20 (2.0) 1.50 ± 0.20 (2.0) 
    
(3) THC-COOH 
   
AUC(0-24) (pmol×h/ml) 61.90 ± 18.99 (35.22) 57.60 ± 11.66 (49.63) 53.94 ± 10.03 (45.5) 
Cmax (pmol/ml) 8.21 ± 2.15 (6.05) 10.32 ± 2.40 (8.06) 8.26 ± 1.35 (7.84) 
Tmax (h) 2.89 ± 0.68 (2.0) 1.56 ± 0.18 (2.0) 2.11 ± 0.26 (2.0) 
    
(4) CBN 
   
AUC(0-24) (pmol×h/ml) 10.17 ± 1.31 (10.8) 11.21 ± 2.28 (9.23) 11.55 ± 2.03 (11.32) 
Cmax (pmol/ml) 1.59 ± 0.19 (1.64) 1.95 ± 0.28 (2.05) 1.66 ± 0.29 (1.52) 
Tmax (h) 2.11 ± 0.39 (2.0) 2.33 ± 0.44 (2.0) 2.11 ± 0.39 (2.0) 
    
(5) CBD 
   
AUC(0-24) (pmol×h/ml) 6.11 ± 0.95 (7.87) 4.85 ± 0.46 (5.25) 3.34 ± 0.68 (2.65) 
Cmax (pmol/ml) 3.68 ± 1.03 (2.49) 3.20 ± 0.36 (2.92) 2.30 ± 0.36 (1.75) 
Tmax (h) 1.17 ± 0.36 (1.0) 0.78 ± 0.09 (1.0) 0.72 ± 0.09 (0.5) 
    
6) Sum [(1) – (4)] 
   
AUC(0-24) (pmol×h/ml) 84.36 ± 20.84 (58.29) 84.84 ± 12.13 (79.12) 76.59 ± 10.34 (58.29) 
Cmax (pmol/ml) 10.86 ± 2.46 (9.18) 15.54 ± 2.60 (14.32) 11.60 ± 1.49 (9.18) 
Tmax (h) 2.89 ± 0.68 (2.0) 1.56 ± 0.18 (2.0) 2.11 ± 0.26 (2.0) 
    
Ratio to unheated 
extract study I    
AUC(0-24) (%) 134.91 135.88 122.49 
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Figure 2: 2a-e: Mean ± SEM plasma concentrations of THC, 11-OH THC, THC-COOH, CBN, CBD 
(pmol/ml) in study part II. 2f: Mean ± SEM plasma concentration of total THC and metabolites (11-OH 
THC, THC-COOH, CBN) (pmol/ml) in study part II 
 
2a 2b 
2c 2d 
2e 2f 
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Besides a bioavailability enhancing effect, addition of TPGS leads to a qualitatively 
different pattern of cannabinoid metabolites (Table 6). 
 
Table 6: Percentage of total AUC (0-24h) of different metabolites of unheated extracts (Parts I and II) 
Form THC 11-OH-THC THC-COOH CBD CBN 
Form C 
0% TPGS 
15.82 ± 3.32 
(11.37) 
10.42 ± 1.69 
(12.30) 
48.55 ± 6.82 
(55.34) 
14.85 ± 4.40 
(12.56) 
10.35 ± 3.00 
(5.67) 
Form D 
0.5% TPGS 
8.67 ± 2.31 
(5.59) 
6.92 ± 1.09 
(6.37) 
61.18 ± 4.54 
(55.18) 
8.61 ± 1.82 
(5.54) 
14.62 ± 2.94 
(12.84) 
Form E 
5.0% TPGS 
11.78 ± 1.86 
(11.19) 
6.76 ± 1.13 
(6.10) 
60.97 ± 3.75 
(60.60) 
5.94 ± 5.32 
(0.78) 
14.55 ± 3.22 
(13.67) 
 
   
C: P = 0.065 
 
Form F 
7.5% TPGS 
6.85 ± 1.78 
(5.06) 
8.07 ± 2.03 
(5.93) 
64.91 ± 3.45 
(65.93) 
4.28 ± 0.60 
(4.77) 
15.89 ± 2.41 
(15.98) 
 
C: P = 0.057 
 
C: P = 0.098 C: P = 0.021 
 
 
 
With the exception of 11-OH-THC, all other cannabinoids showed systematic changes 
of their proportion with increasing TPGS content of unheated cannabis extracts when 
compared to the results of the unheated extract without TPGS used in study part I: 
THC proportion decreased from 15.82 ± 3.32 (11.37) % (Form C) over 8.67 ± 2.31 
(5.59) % (Form D) and 11.78 ± 1.86 (11.19) % (Form E) to finally 6.85 ± 1.78 (5.06) % 
(Form F). The latter proportion was borderline significantly lower (P = 0.057) than that 
of Form C. THC-COOH proportion increased from 48.55 ± 6.82 (55.34) % (Form C) 
over 61.18 ± 4.54 (55.18) % (Form D) and 60.97 ± 3.75 (60.60) % (Form E) to finally 
64.91 ± 3.45 (65.93) % (Form F). The latter proportion was borderline significantly 
higher (P = 0.098) than that of Form C.  
 
CBD proportion decreased from 14.85 ± 4.40 (12.56) % (Form C) over 8.61 ± 1.82 
(5.54) % (Form D) and 5.94 ± 5.32 (0.78) % (Form E) (P = 0.065) to finally 4.28 ± 
0.60 (4.77) % (Form F). The latter proportion was borderline significantly lower (P = 
0.021) than that of Form C. 
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There was a trend of increasing proportions of CBN with increasing TPGS content: 
CBN proportion increased from 10.35 ± 3.00 (5.67) % (Form C) over 14.62 ± 2.94 
(12.84) % (Form D) and 14.55 ± 3.22 (13.67) % (Form E) (P = 0.065) to finally 15.89 
± 2.41 (15.98) % (Form F). However, none of these changes reached statistical 
significance.  
 
 
4. Discussion and overall conclusion 
 
The study was performed in two parts: In the first part, the relative bioavailabilities of 
a heated and an unheated Cannabis sativa L. extract (containing 20 mg THCtot and 
20 - 30 mg CBDtot) was compared to 20 mg synthetic THC. In the second study part, 
the effect of the addition of different amounts of TPGS to the cannabis extracts on 
the bioavailabilities of cannabinoids has been investigated. 
 
The pharmacokinetics of cannabinoid metabolites showed a high inter-subject 
variability. The median relative oral bioavailability of the heated and unheated extract 
(versus MarinolTM) was 83.3% and 60.4%. The metabolic pattern of cannabinoid 
metabolites after administration of MarinolTM and the heated and unheated Cannabis 
sativa L. extract was qualitatively different with a significantly higher relative 
bioavailability of THC and CBD and a significantly lower relative bioavailability of 
THC-COOH. This could be the result of changes in the absorption of cannabinoid 
metabolites, in changes in metabolic activity or elimination processes. With this 
experimental design, the cause(s) of the change(s) could not be identified. 
 
Addition of different amounts of TPGS resulted in an increase in relative 
bioavailability of the sum of cannabinoid metabolites (THC + 11-OH-THC + THC-
COOH + CBN) to 122.5% (7.5% TPGS), 134.9% (0.5% TPGS) and 135.9% (5% 
TPGS) compared with the AUC of the unheated extract (=100%) in study part I. 
However, the weakness of this assessment is, that the AUC of the unheated extract 
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without addition of TPGS was determined in part I of the study, hence in a different 
subject population. 
 
There was an indication that addition of TPGS resulted in a dose-dependent effect on 
the metabolic pattern of cannabinoid metabolites. Since TPGS is known to interact 
with efflux pumps (such as p-glycoprotein [12, 138, 141, 142]) it may also effect the 
enteral absorption of some of the cannabinoids. Whether it effects also metabolic 
reactions of cannabinoid is not known. 
 
It can, therefore, be concluded that the administration of Cannabis sativa L. extracts 
is safe. These extracts have a slightly lower bioavailability of total cannabinoids than 
MarinolTM. However, the pharmacological effects seem to be comparable. Addition of 
TPGS increases the bioavailability of cannabinoids up to about 35% compared to 
extracts without TPGS without deteriorating tolerability. 
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4. Conclusions and outlook 
 
Since the United States FDA approved MarinolTM (a synthetic THC medication) to 
treat nausea and vomiting associated with cancer chemotherapy and to treat appetite 
loss associated with weight reduction in people with AIDS, the interest in additional, 
possible clinical indications of cannabis preparations increased. A cannabis extract 
formulation is supposed to have less adverse side effects than a synthetic one 
because of a well-balanced combination of active substances which can be found in 
the natural cannabis plant. 
 
Therefore, a clinical trial with different Cannabis sativa L. extracts and MarinolTM was 
performed to analyse the pharmacokinetics and pharmacodynamics of the 
cannabinoids and to evaluate the best Cannabis sativa L. extract capsule formulation 
in this clinical phase I study for a possible future implementation as a new, 
concomitant medicament in cancer, HIV and AIDS therapies. 
 
First, a sensitive LC-MS/MS method was developed for the simultaneous detection 
and quantification of the main cannabinoids THC, 11-OH-THC, THC-COOH, CBD 
and CBN in human plasma and urine. Optimal conditions for the analysis method, 
such as extraction procedure, matrices, column, quality controls, wavelength, mobile 
phases, run time, optimal separation (gradient, retention times), temperature, 
voltages, vacuum and internal standards, resulting in the best sensitivity and 
selectivity, were developed in preliminary experiments. 
 
The validation of the method was performed according to the FDA Good Laboratory 
Practice guidelines, containing linear measuring range, quantification, lower limit of 
quantification (LLOQ), lower limit of detection (LLOD), quality controls, precision, 
accuracy, recovery, stability and matrix effects. 
 
In conclusion, the described high-performance liquid chromatographic separation 
method with tandem-mass spectrometry detection showed a satisfactory overall 
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analytical performance well suited for applications in medical science. The 
combination of SPE/LLE, LC and APCI-MS/MS represents an attractive alternative to 
the well-established technique of GC-MS. 
 
Second, the sensitivity and specificity of two immunoassays (CEDIA, FPIA) were 
established in urinary samples from volunteers receiving oral synthetic THC or 
Cannabis sativa L. extracts. Urinary THC-COOH excretion was evaluated by the 
immunoassays with a cut-off value of 50 ng/ml as well as the described LC-MS/MS 
method (gold standard) with a cut-off value of 15 ng/ml. It was demonstrated that LC-
MS/MS is an excellent confirmation method for immunoassays allowing the 
qualitative and quantitative detection of many cannabinoids. The ROC analysis 
indicated that the FPIA test discriminates better between users and non-users than 
the CEDIA test. The results of both immunoassays show that the SAMHSA set 
general immunoassay cut-off of 50 ng/ml is possibly not applicable for analysis of 
samples from persons consuming the Cannabis sativa L. extracts orally instead of 
smoking. It has to be discussed whether a lower cut-off value would be 
advantageous. It is supposed that metabolite concentrations differ strongly 
depending on the route of application. The amount and appearance of different 
metabolites may disturb the immunoassay methods. 
 
The glucuronide hydrolysation procedure showed a total transformation of the THC-
COOH-glucuronides to THC-COOH confirmed by the nearly 100% agreement of 
the concentrations in the different samples analysed with the two immunoassays 
and the LC-MS/MS comparisons. The glucuronide is automatically detected 
together with THC-COOH and it is direct de-glucuronated in the APCI unit of the 
detector. 
 
In conclusion, the use of cannabinoid-based therapeutics and continued abuse of 
oral cannabis products require scientific data for accurate interpretation of 
cannabinoid tests and for establishing a reliable administrative drug-testing policy. 
Preliminary positive immunoassay results have to be confirmed by a second, more 
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specific analysis method like GC-MS or LC-MS. To get correct quantitative results of 
the analytes, it is important to include the glucuronides in the analysis. 
 
Third, a clinical trial was performed. In the first study part, the relative bioavailabilities 
of a heated and an unheated Cannabis sativa L. extract was compared to MarinolTM. 
In the second study part, the effect of the addition of different amounts of TPGS to 
the cannabis extracts on the bioavailabilities of cannabinoids has been investigated. 
 
The pharmacokinetics of the cannabinoids was highly variable between the subjects. 
Due to this variability, no statistically significant differences between the AUC of the 
different forms could be detected, neither in part I nor in part II of the study.  
 
Addition of different amounts of TPGS resulted in an increase in relative 
bioavailability of the sum of cannabinoid metabolites (THC + 11-OH-THC + THC-
COOH + CBN) to 122.5% (7.5% TPGS), 134.9% (0.5% TPGS) and 135.9% (5% 
TPGS) compared with the AUC of the unheated extract (=100%) in study part I. The 
administration of cannabis extracts as well as the addition of TPGS leads to a 
qualitatively different pattern of cannabinoid metabolites. After administration of the 
unheated extract, a significantly higher proportion of THC AUC and a significantly 
lower THC-COOH AUC of all cannabinoids were observed compared to the heated 
extract or MarinolTM. After administration of the synthetic MarinolTM, no plasma 
concentrations of CBD could be detected. This was expected, since THC is not 
converted to CBD in vivo and CBD is found only in cannabis plants. Heating of 
extracts decreased the proportion of CBD significantly. 
 
It can be concluded that the administration of Cannabis sativa L. extracts is safe. The 
extracts have a slightly lower bioavailability of total cannabinoids than MarinolTM. 
However, the pharmacological effects seem to be comparable. The future approach 
will address further research. The 5% Cannabis sativa L. extract capsule formulation 
showed a marginal higher increase in relative bioavailability than the 0.5% one. 
However, the 0.5% TPGS formulation contains more CBD than the 5% one. The 
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importance of a high CBD concentration (less adverse effects) has to be discussed 
for the development of a new medication. Further clinical studies with the 5% or 0.5% 
TPGS Cannabis sativa L. extract capsule formulations may be helpful. The study 
should be placebo controlled and later tested in the future patient group. 
 
For a better understanding of cannabis consumption and the cannabis metabolism in 
the human body, the detection of further cannabinoids like THCA-A would be useful. 
THCA-A may prove an interesting field for the interpretation of cannabis consumption 
habits (single/frequent intake). If THCA-A shows a shorter elimination half-life time 
and a lower partition coefficient than THC it is important for the estimation of the 
elapsed time between the last intake and blood sampling. Therefore, THCA-A might 
be detectable only a very short time after cannabis consumption. The detection of 
THCA-A is a field of trace analysis. Therefore, a sensitive method with a low LLOQ is 
necessary for future investigations. 
 
Future cannabinoid detection for criminal and forensic purposes requires analyses 
methods in additional matrices like hair or saliva. It can be difficult to detect the used 
drugs (active products at low dosages, chemical instability). The drug can be quickly 
eliminated from body fluids or in case of long delay between the alleged crime and 
clinical examination, collection of blood or urine can be of little value. The non-
invasive collection of a saliva sample, which is relatively easy to perform and can be 
achieved under close supervision, is one of the most important benefits in a driving 
under the influence situation. Moreover, the presence of THC in oral fluid is a better 
indication of recent use than when the drug is detected in urine. The probability is 
higher that the subject is experiencing pharmacological effects at the time of 
sampling. Due to a long delay between an alleged crime and the clinical examination, 
hair testing can be very useful but depending on the hair colour of a human being 
drug detection is possible for months after crime. 
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